

**DUKE UNIVERSITY MEDICAL CENTER
CURRICULUM VITAE**

NAME: Ashwin Anand Patkar, MD, MRCPsych

**PRIMARY ACADEMIC:
APPOINTMENT** Associate Professor, Psychiatry and Behavioral Sciences

**PRIMARY ACADEMIC:
DEPARTMENT** Psychiatry and Behavioral Sciences

**SECONDARY ACADEMIC:
APPOINTMENT** None

**PRESENT ACADEMIC:
RANK AND TITLE** Associate Professor, Psychiatry and Behavioral Sciences, Duke University, Durham, NC 27704

**PRESENT CLINICAL:
TITLE** Medical Director, Duke Addictions Program

OTHER TITLES: Associate Director, Neuroscience Medicine, Duke Clinical Research Institute

HOME ADDRESS: 313 Belles Landing Court , Cary, NC 27519.
OFFICE ADDRESS: 2218 Elder Street, Suite 201, Durham, NC 27705.
TELEPHONE: (919) 465-2660 (H), (919) 668-3626 (W)
FAX: (919) 668-5418
E-MAIL: ashwin.patkar@duke.edu

MEDICAL LICENSURE: North Carolina Full Unrestricted License # 200400396
Commonwealth of Pennsylvania Full Unrestricted License (MD-061476-L).

DATE OF LICENSURE: April 9, 1997 (Pennsylvania), April 22, 2004 (North Carolina)

DEA CERTIFICATE: 1. BP5335066 (expires 03/09)
2. XP5335066 (expires 03/09) (special certificate to prescribe buprenorphine)

ECFMG CERTIFICATE: #0-479-465-7 (issued Jan 11, 1995).

SPECIALTY 1. Psychiatry (American Board of Psychiatry & Neurology) May 1999. Recertification 2010

**CERTIFICATIONS:
& DATES (MM/DD/YR)** 2. Addiction Psychiatry (American Board of Psychiatry & Neurology) April 2000, Recertification 2010
3. Addiction Medicine (American Society of Addiction Medicine) Nov 1998, Recertification 2009
4. Diplomate, American Board of Addiction Medicine, 2009
5. Psychiatry (Royal College of Psychiatrists, England) July 1993.
6. Psychiatry (University of Bombay, India) January 1989

BIRTH DATE: November 17, 1963

PLACE OF BIRTH: Bombay, India.

CITIZEN OF: United States of America.

EDUCATION:

	<u>Institution</u>	<u>Date (Year)</u>	<u>Degree</u>
High School	King George School, Bombay	72-80	
College	Dongarsee Gangjee(D.G.) Ruparel College, University of Bombay	80-82	
Professional School	Gordhandas Sundardas(G.S.) Medical College, University of Bombay	82-88	MBBS (Bachelor of Medicine & Bachelor of Surgery)
Professional School	University of Bombay	88-89	MD (Psychiatry)
Post Graduate	University of Nottingham	93-95	M.Phil (Neuropharmacology)

SCHOLARLY SOCIETIES:

American Psychiatric Association.
 American Medical Association
 Royal College of Psychiatrists.
 American Academy of Addiction Psychiatry (AAAP).
 American Society of Addiction Medicine (ASAM).
 Association for Medical Education and Research in Substance Abuse
 (AMERSA).
 Indian Psychiatric Society.
 World Psychiatric Association.
 North Carolina Medical Society
 North Carolina Psychiatric Association

**PROFESSIONAL TRAINING
& ACADEMIC APPOINTMENTS:**

<u>Institution</u>	<u>Position/Title</u>	<u>Date (Year)</u>
Seth G.S. Medical College & King Edward VII Memorial (KEM) Hospital, University of Bombay, India.	Resident in Psychiatry	2/1987- 1/90
Seth G.S. Medical College & King Edward VII Memorial (KEM) Hospital, University of Bombay, India.	Lecturer in Psychiatry	2/1990- 8/90
University of Nottingham (Mid-Trent) Regional Registrar Training Scheme Nottingham, England	Resident in Psychiatry	8/1990- 7/94
Drug & Alcohol Team, Mapperley Hospital, Nottingham, England	Fellowship in Addiction	8/1994- 3/95
Thomas Jefferson University Hospital & Thomas Jefferson University, Philadelphia, PA	Intern & Resident in Psychiatry	4/1995- 4/97
Thomas Jefferson University & Thomas Jefferson University Hospital, Philadelphia, PA	Instructor in Psychiatry	5/1997- 6/99

Thomas Jefferson University & Thomas Jefferson University Hospital, Philadelphia, PA	Assistant Professor in Psychiatry	7/1999- 6/02
Thomas Jefferson University & Thomas Jefferson University Hospital, Philadelphia, PA	Associate Professor in Psychiatry	7/02- 9/04
Duke University & Duke University Medical Center Durham, NC	Associate Professor in Psychiatry	10/04-continues
Duke Clinical Research Institute (DCRI), Durham NC	Associate Director-Neuroscience Medicine	7/09-continues

CLINICAL APPOINTMENTS:

Thomas Jefferson University Hospital Philadelphia, PA:	Active Medical Staff	5/1997- 9/2004
Thomas Jefferson University Philadelphia, PA:	Director of Biological Psychiatry & Clinical Trials	7/ 2002-9/2004
Thomas Jefferson University Hospital Philadelphia, PA:	Associate Director Comprehensive Center for Tobacco Research and Treatment	7/1999-9/2004
Thomas Jefferson University Philadelphia, PA:	Associate Medical Director Intensive Outpatient Substance Abuse Treatment Program & Methadone Maintenance Program	5/1997-9/2004
Duke University Medical Center Durham, NC27710	Active Medical Staff	10/04- continues
Durham Regional Hospital, Durham, NC 27704	Active Medical Staff	11/04-continues
Duke Specialty Clinic in Psychiatry Cary, NC	Associate Director	6/06- continues

PUBLICATIONS:

1. Refereed Journals:

- 1) Patkar AA, Shah LP and Pradhan PV (1989). Tertiary Syphilis presenting as manic depressive psychosis. *Indian Journal of Psychiatry* 31:261-263.
- 2) Patkar AA, Pradhan PV and Shah LP (1990). Prepubertal bipolar disorder with 30 day spontaneous, classic, rapid cycles. *Indian Journal of Psychiatry* 32:93-94.
- 3) Patkar AA & Shah LP (1991) Neuroleptic malignant syndrome. *Journal of Postgraduate Medicine* 37:168-170.
- 4) Patkar AA & McLean PC (1994) Drug misusers in police custody. *Journal of Royal Society of Medicine* 87:720.

- 5) Patkar AA, Naik P, Al-Chalabi T, Kendall DA, Marsden CA (1995) Platelet (3)H Imipramine binding in type I and type II alcoholism. *Human Psychopharmacology* 10:1-6.
- 6) Patkar AA & Alexander RC (1996) Clozapine induced parotid enlargement. *Journal of Clinical Psychiatry* 57: 487.
- 7) Patkar AA & Kunkel E (1997) Delirium in elderly patients. *Psychiatric Services* 48: 46-48.
- 8) Patkar AA, Peng A & Alexander RC (1997) Neurosyphilis occurring in a patient with schizophrenia: a cautionary tale. *Journal of Nervous and Mental Disease* 14:119-120.
- 9) Alexander RC, Patkar AA, McCarthy HH & Horner R (1997) Schizencephaly and psychosis. *Journal of Neurology, Neuropsychiatry and Psychiatry* 24:345-347.
- 10) Patkar AA, Sterling R, Gottheil E & Weinstein SP (1999) A comparison of medical symptoms reported by cocaine, opiate and alcohol dependent persons. *Substance abuse* 20:227-236.
- 11) Patkar, AA, Alexander R C, Lundy A and Certa K (1999) Changing patterns of substance use among schizophrenic patients: 1984-1996. *The American Journal on Addictions* 8:65-71.
- 12) Patkar AA, Hill KP, Weinstein SP and Schwartz SL (2000) ECT in the presence of increased intracranial pressure: Evaluation and reduction of risk. *Journal of Electroconvulsive Treatment* 16: 17-26.
- 13) Patkar AA, Berrettini WH, Hill KP, Wendel B, Sterling RC, Gottheil E, Weinstein SP (2001) Serotonin transporter polymorphisms among Cocaine-Dependent Individuals. *Addiction Biology* 6:337-345.
- 14) Batra V, Patkar AA, Weibel S, Leone FT (2002) Tobacco smoking as a chronic disease: notes on prevention and treatment. *Clinics in Office Practice* 29:1-20.
- 15) Batra V, Patkar AA, Weibel S, Pincock G, Leone FT (2002). Public health implications of voters' attitudes regarding statewide tobacco policy. *Chest* 122: 295-298.
- 16) Patkar AA, Hill KP, Sterling RC, Gottheil E, Berrettini WH, Weinstein SP (2002) Serum Prolactin and Response to Treatment among Cocaine-Dependent Individuals. *Addiction Biology* 7: 45-53.
- 17) Patkar AA, Lundy A, Leone FT, Weinstein SP, Gottheil E, Steinberg M (2002) Tobacco and alcohol use and medical symptoms among cocaine dependent patients. *Substance Abuse* 23:105-113.
- 18) Patkar AA, Sterling RC, Leone FT, Lundy A, Weinstein SP (2002) Relationship between tobacco smoking and medical symptoms among cocaine, alcohol and opiate dependent patients. *American Journal on Addictions* 11:209-218.
- 19) Patkar AA, Berrettini WH, Hoehe M, Hill KP, Thornton CC, Gottheil E, Weinstein SP (2002) No association between polymorphisms in a variable-number-tandem-repeat region of the serotonin transporter gene and cocaine dependence. *Psychiatric Genetics* 12:161-164.
- 20) Patkar AA, Berrettini WH, Hoehe M, Thornton CC, Gottheil E, Weinstein SP (2002) Serotonin transporter polymorphisms and measures of impulsivity, aggression and sensation seeking among African-American cocaine-dependent individuals. *Psychiatry Research* 110:103-115.
- 21) Patkar AA, Thornton CC, Berrettini, WH, Gottheil E, Weinstein SP, Hill KP (2002) Predicting treatment-outcome in cocaine dependence from admission urine drug screen and peripheral serotonergic measures *Journal of Substance Abuse Treatment* 23: 33-40.

- 22) Patkar AA, Gopalakrishnan R, Lundy A, Leone FT, Certa KM, Weinstein SP (2002) Relationship between tobacco smoking and positive and negative symptoms in schizophrenia. *Journal of Nervous and Mental Disease* 190: 1-7.
- 23) Zeiger AR, Patkar AA, Ballas S, Fitzgerald R, Lundy A and Weinstein SP (2002) Changes in mu opioid receptors and rheological properties of erythrocytes among opioid abusers. *Addiction Biology* 7: 207-217.
- 24) Batra, V, Patkar AA, Berrettini WH, Weinstein SP, Leone FT (2003) The genetic determinants of smoking. *Chest* 123:1730-1739.
- 25) Batra V, Patkar AA, Berrettini WH, Weinstein SP, Leone FT (2003) Genetic determinants of nicotine dependence. *Chest* 123:1730-1739.
- 26) Crowley JJ, Oslin DW, Patkar AA, Gottheil E, DeMaria PA Jr., O'Brien CP, Berrettini WH, Grice DE (2003) A genetic association study of the mu-opioid receptor and severe opioid dependence *Psychiatric Genetics* 14: 7-13.
- 27) DeMaria P, Patkar AA, Vassos K (2003) Fluvoxamine as an adjunct to promote methadone dose optimization. *Addictive Disorders and their Treatment* 2:85-89.
- 28) Khurana S, Batra V, Patkar AA, Leone FT (2003) Twenty-first Century Tobacco Use: It's Not Just a Risk Factor Anymore. *Respiratory Medicine* 97:295-301.
- 29) Murray HW, Patkar AA, Mannelli P, Desai A, DeMaria P, Vergare MJ (2003) Relationship of aggression, sensation seeking and impulsivity with severity of cocaine use *The Journal of Addictive Disorders and Their Treatment* 2: 127-137.
- 30) Patkar AA, Gottheil E, Berrettini, WH, Thornton CC, Hill KP, Weinstein SP (2003) Platelet Tritiated Paroxetine Binding and Treatment Outcome among African-American Cocaine Dependent Individuals. *Journal of Addictive Diseases* 22:79-92.
- 31) Patkar AA, Gopalakrishnan R, Berrettini WH, Weinstein SP, Vergare MJ, Leone FT (2003) Differences in platelet serotonin transporter sites between African-American tobacco smokers and nonsmokers *Psychopharmacology* 166:221-227.
- 32) Patkar AA , Bilal LA, Masand PS (2003) Management of fibromyalgia. *Current Psychiatry Reports* 5:4-11.
- 33) Patkar A A, Vergare MJ, Batra V, Weinstein SP, Leone FT (2003) Tobacco smoking: current concepts in etiology and treatment. *Psychiatry: interpersonal and biological processes* 66:183-189.
- 34) Patkar AA, Berrettini WH, Lundy A, Murray H, Hill KP, Vergare MJ, Weinstein SP (2003) Seasonal variations in the binding of [³H] paroxetine to platelet serotonin transporter sites in African-American cocaine-dependent patients and healthy volunteers. *Human Psychopharmacology Clinical and Experimental* 18:103-111.
- 35) Patkar AA, Vergare M, Thornton CC, Weinstein SP, Leone FT (2003) Tobacco smoking and treatment-outcome among African-American cocaine dependent patients *Nicotine and Tobacco Research* 5:48-55.
- 36) Patkar AA, Gottheil E, Berrettini, WH, Hill KP, Thornton CC, Weinstein SP (2003) Relationship between platelet serotonin uptake sites and measures of impulsivity, aggression and sensation seeking among cocaine abusers. *American Journal on Addictions* 12:1-16.
- 37) Patkar AA, Gopalakrishnan R, Naik PC, Murray HW, Vergare MJ, Marsden CA (2003) Changes in noradrenaline and serotonin levels and craving during alcohol withdrawal. *Alcohol and Alcoholism* 38: 224-231.
- 38) Patkar AA, Hill KP, Batra V, Vergare MJ, Leone FT (2003) A comparison of smoking habits among medical and nursing students in 2000. *Chest* 24: 1415-1420.

- 39) Thornton CC, Patkar AA, Murray HW, Mannelli P, Gottheil E, Weinstein SP (2003) High- and low-structure treatments for substance dependence: Role of Learned Helplessness. *American Journal of Drug and Alcohol Abuse* 29:567-584.
- 40) Thornton CC, Gottheil E, Patkar AA, Weinstein SP (2003) Coping styles and response to high versus low structure individual counseling for substance abuse. *American Journal on Addictions* 12:29-42.
- 41) Masand PS, Fazal F, Patkar AA (2004) Safety considerations in the pharmacotherapy of bipolar disorder. In Press. *CNS Spectr.* 9:16-26.
- 42) Patkar AA, Berrettini WH, Gopalakrishnan R, Mannelli P, Hoehe M, Bilal LA, Gottheil E, Vergare MJ Relationship between serotonin transporter gene polymorphisms and platelet serotonin transporter sites among African-American cocaine dependent individuals and healthy volunteers (2004) *Psychiatric Genetics* 14:25-32.
- 43) Patkar AA, Marsden CA, Naik PC, Kendall DA, Gopalakrishnan R, Weinstein SP (2004) Differences in peripheral noradrenergic function in actively drinking and recently abstinent alcohol-dependent individuals. *American Journal on Addictions* 13:225-235.
- 44) Patkar AA, Murray HW, Gopalakrishnan R, Lundy A, Weinstein SP, Vergare MJ (2004) Pre-treatment measures of impulsivity, aggression and sensation-seeking predict treatment-outcome for African-American Cocaine Dependent Individuals. *Journal of Addictive Diseases* 23:109-122.
- 45) Patkar AA, Thornton CC, Mannelli P, Hill KP, Gottheil E, Vergare MJ (2004) A comparison of pre-treatment characteristics and treatment-outcome for alcohol-, cocaine- and multisubstance-dependent individuals. *Journal of Addictive Diseases* 23:93-109.
- 46) Patkar AA, Mannelli P, Peindl K, Murray H, Vergare MJ, Berrettini WH (2004) Relationship of serum prolactin with severity of drug use and treatment-outcome in cocaine dependence. *Psychopharmacology* 17:68-76.
- 47) Patkar AA , Mago R, Masand PS. (2004) Psychotic symptoms in patients with medical disorders *Curr Psychiatry Rep.* 6:216-224.
- 48) Patkar AA , Bilal LA, Masand PS (2004) Pharmacotherapy of depression in pregnancy *Annals of Clinical Psychiatry* 16:87-100.
- 49) Mannelli P, Patkar AA, Murray HW, Certa K, Peindl K, Mattila-evenden M, Berrettini WH (2005) Polymorphism in the serotonin transporter gene and response to treatment in African-American cocaine and alcohol abusing individuals *Addiction Biology* 10:261-268.
- 50) Meier B, Lundy A, Patkar AA, Weinstein SP (2005) The relation between nicotine dependence and addiction severity among cocaine abusers. *Journal for Substance Use* 10: 303-314.
- 51) Patkar AA, Batra V, Mannelli P, Evers-Casey S, Vergare MJ, Leone FT (2005) Medical symptoms associated with tobacco smoking with and without marijuana abuse among crack cocaine abusers *American Journal on Addictions* 14: 43-53.
- 52) Peindl KS, Weinstein SP, Patkar AA, Vergare MJ (2005) ACGME Research Requirements for Residents in Psychiatry. *Academic Psychiatry* 28: 354
- 53) Smith RJ, Doyle GA, Han AM, Crowley JJ, Oslin DW, Patkar AA, Mannelli P, Demaria PA Jr, O'brien CP, Berrettini WH (2005) Novel exonic mu-opioid receptor gene (OPRM1) polymorphisms not associated with opioid dependence *Am J Med Genet.* 133B:105-109.

- 54) Mannelli P, Patkar AA, Murray HW, Certa K, Peindl K, Mattila-evenden M, Berrettini WH (2006) Polymorphism in the serotonin transporter gene and response to metachlorophenylpiperazine (m-CPP) in cocaine abusers *Psychiatry Research* 144:99-108.
- 55) Masand PS, Narasimhan M, Patkar AA (2006) Paroxetine for somatic pain associated with physical illness: a review. *Prim Care Companion J Clin Psychiatry* 8:122-130.
- 56) Masand PS, Tharwani H, Patkar AA (2006) Polypharmacy in schizophrenia. *International Journal of Psychiatry in Clinical Practice*.10:258-263
- 57) Pae CU, Serretti A, Mandelli L, Yu HS, Patkar AA, Lee CU, Lee SJ, Jun TY, Lee C, Paik IH, Kim JJ (2006). Effect of 5-haplotype of dysbindin gene (DTNBP1) polymorphisms for the susceptibility to bipolar I disorder. *Am J Med Genet B Neuropsychiatr Genet* 6:112-119.
- 58) Pae CU, Patkar AA, June TY, Lee CU, Masand PS, Paik IH (2006) Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. *Depression Anxiety* 16:29-34.
- 59) Pae CU, Yu HS, Amann D, Kim JJ, Lee CU, Lee SJ, Jun TY, Lee C, Paik IH, Patkar AA, Lerer B (2006) Association of the trace amine associated receptor 6 (TAAR6) gene with schizophrenia and bipolar disorder in a Korean case control sample. *J Psychiatr Res* 28: 221-229.
- 60) Pae CU, Yoon SJ, Patkar AA, Kim JJ, Jun TY, Lee C, Paik IH (2006). Manganese superoxide dismutase (MnSOD: Ala-9Val) gene polymorphism and mood disorders: a preliminary study. *Prog Neuropsychopharmacol Biol Psychiatry* 30:1326-1329.
- 61) Pae CU, Nassir Ghaemi S, Patkar AA, Chae JH, Bahk WM, Jun TY, Masand P. (2006) Adjunctive risperidone, olanzapine and quetiapine for the treatment of hospitalized patients with bipolar I disorder: a retrospective study *Prog Neuropsychopharmacol Biol Psychiatry* 30:1322-1325.
- 62) Pae CU, Kim TS, Lee KU, Kim JJ, Patkar AA, Masand PS, Ghaemi SN, Lee CU, Lee SJ, Lee C, Paik IH (2006) Clinical variables associated with early administration of antipsychotics in bipolar mania. *Prog Neuropsychopharmacol Biol Psychiatry* 30:151-154.
- 63) Patkar AA, Mannelli P, Peindl K, Gopalakrishnan, R, Handelsman L, Berrettini WH (2006). Relationship of impulsivity and aggression with responses to metachlorophenylpiperazine (m-CPP) in cocaine abusers. *Psychopharmacology* 1: 1-10
- 64) Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, Ciccone P (2006) A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. *J Clin Psychopharmacol*.26:653-656.
- 65) Patkar AA, Mannelli P, Hill KP, Peindl K, Pae C, Lee T, Berrettini WH (2006). Severity of cocaine use in associated with responses to metachlorophenylpiperazine (m-CPP) in cocaine abusers. *Human Psychopharmacology* 21:367-75.
- 66) Patkar AA, Mannell P, Murray HW, Peindl K, Gopalakrishnan R, Leone FT (2006) Changes in tobacco smoking following treatment for cocaine dependence. *The American Journal of Drug and Alcohol Abuse* 32:135-148.
- 67) Patkar AA, Peindl KP, Mago R, Mannelli P, Masand PS (2006) An open-label trial of augmentation with aripiprazole in treatment-resistant depression. *Primary Care Companion, Journal of Clinical Psychiatry* 8:82-87.
- 68) Patkar AA, Pae C, Masand PS. (2006) Transdermal selegiline: the new generation of monoamine oxidase inhibitors. *CNS Spectrums* 11:363-375.

- 69) Davidson C, Gopalan R, Ahn C, Chen Q, Mannelli P, Patkar AA, Weese GD, Lee TH, Ellinwood EH (2007) Reduction in methamphetamine induced sensitization and reinstatement after combined pergolide plus ondansetron treatment during withdrawal. *Eur J Pharmacol.* 565:113-118
- 70) Han C, Lee M, Pae CU, Ko Y, Patkar AA, Jung I (2007) Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 31:1219-1223.
- 71) Hubbard RL, Leimberger JD, Haynes L, Patkar AA, Holter J, Liepman MR, Lucas K, Tyson B, Day T, Thorpe EA, Faulkner B, Hasson A (2007) Telephone enhancement of long-term engagement (TELE) in continuing care for substance abuse treatment: a NIDA clinical trials network (CTN) study. *Am J Addict.* 16:495-502
- 72) Kim JJ, Mandelli L, Pae CU, De Ronchi D, Jun TY, Lee C, Paik IH, Patkar AA, Steffens D, Serretti A, Han C (2007) Is there protective haplotype of dysbindin gene (DTNBP1) 3 polymorphisms for major depressive disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 32:375-379.
- 73) Mannelli P, Peindl K, Masand PS, Patkar AA (2007) Long acting injectable naltrexone for the treatment of alcohol dependence. *Expert Rev Neurother.* 7:1265-1277.
- 74) Meier BR and Patkar AA (2007) Buprenorphine Treatment: Factors and First-Hand Experiences for Providers to Consider. *Journal of Addictive Diseases* 26:3-14.
- 75) Pae CU and Patkar AA (2007) Paroxetine: Current Status in Psychiatry. *Expert Review of Neurotherapeutics* 7:107-20
- 76) Pae CU, Kim JJ, Lee CU, Lee SJ, Lee C, Patkar AA, Masand PS, Paik IH (2007). Rapid versus conventional initiation of quetiapine in the treatment of schizophrenia: a randomized, parallel-group trial. *J Clin Psychiatry.* 68:399-405.
- 77) Pae CU, Serretti A, Mandelli L, De Ronchi D, Patkar AA, Jun TY, Kim JJ, Lee CU, Lee SJ, Lee C, Paik IH (2007) Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy. *Pharmacogenet Genomics* 17:69-75.
- 78) Pae CU, Kim TS, Patkar AA, Kim JJ, Lee SU, Jun TY, Lee C, Paik IH (2007) Manganese superoxide dismutase (MnSOD: Ala-9Val) gene polymorphism may not be associated with schizophrenia and tardive dyskinesia *In Press Psychiatry Research.*
- 79) Pae CU, Mandelli L, Serretti A, Patkar AA, Kim JJ, Lee CU, Lee SJ, Lee C, De Ronchi D, Paik IH (2007) Heat-shock protein-70 genes and response to antidepressants in major depression. *Prog Neuropsychopharmacol Biol Psychiatry* 31:1006-1011
- 80) Pae CU, Lim HK, Ajwani N, Lee C, Patkar AA (2007). Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder. *Expert Rev Neurother.* 7:603-615.
- 81) Patkar AA, Masand PS, Krulewicz S, Peindl KP, Mannelli, P, Beebe K, Jiang Wei (2007) A randomized, double-blind, placebo-controlled trial of controlled release paroxetine in fibromyalgia. *American Journal of Medicine.* 120:448-454.
- 82) Patkar AA Pae CU, Zarzar M (2007) Transdermal Selegiline *Drugs of Today* 43: 361-369.
- 83) Peindl KS, Masand P, Mannelli P, Narasimhan M, Patkar A.(2007) Polypharmacy in pregnant women with major psychiatric illness: a pilot study. *J Psychiatr Pract.* 13:385-392.
- 84) Peindl KS, Mannelli P, Wu LT, Patkar AA (2007) Trends in nonheroin opioid abuse admissions: 1992-2004 *J Opioid Manag* 3:215-223.

- 85) DeMaria PA, Patkar AA (2008) The implementation of buprenorphine/naloxone in college health practice. *J Am Coll Health*. 56:391-393.
- 86) Han C, Pae CU, Lee BH, Ko YH, Masand PS, Patkar AA, Joe SH, Jung IK (2008) Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder: a 12-week prospective, open-label, randomized, parallel-group trial. *Clin Drug Investig*. 28:251-261.
- 87) Han C, Pae CU, Lee BH, Ko YH, Masand PS, Patkar AA, Jung IK (2008) Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: a randomized, open-label, 12-week, parallel-group trial. *Prog Neuropsychopharmacol Biol Psychiatry* 32:437-444.
- 88) Han C, Marks DM, Pae CU, Lee BH, Ko YH, Masand PS, Patkar AA, Jung IK (2008) Paroxetine for patients with undifferentiated somatoform disorder: A prospective, open-label, 8-week pilot study. *Current Therapeutic Research* 69(3).
- 89) Han C, Kwak KP, Marks DM, Pae CU, Wu LT, Bhatia KS, Masand PS, Patkar AA (2008) The impact of the CONSORT statement on reporting of randomized clinical trials in psychiatry. *Contemp Clin Trials* Epub ahead of print
- 90) Mannelli P, Patkar AA, Peindl K, Gorelick DA, Wu LT, Gottheil E (2008) Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial. *Addict Biol*. Epub ahead of print
- 91) Marks DM, Pae CU, Patkar AA (2008) Triple reuptake inhibitors: the next generation of antidepressants. *Current Neuropharmacology Journal*, 6(4).
- 92) Marks DM, Pae CU, Patkar AA (2008) Triple reuptake inhibitors: a premise and promise. *Psychiatry Investigation*;5.
- 93) Marks DM, Pae CU, Patkar AA (2008) Potential role of pregabalin in the treatment of lithium-induced tremor: a case report. *Int J Neuropsychopharmacol*. 11:879-881.
- 94) Marks DM, Han C, Krulewicz S, Pae CU, Peindl K, Patkar AA, Masand PS (2008) History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: post hoc analysis from a placebo-controlled study. *Prim Care Companion J Clin Psychiatry* 10:368-375
- 95) Marks DM, Park MH, Ham BJ, Han C, Patkar AA, Masand PS, Pae CU (2008) Paroxetine: safety and tolerability issues. *Expert Opin Drug Saf*. 7:783-794.
- 96) Masand PS, Pae CU, Krulewicz S, Peindl K, Mannelli P, Varia IM, Patkar AA (2009) A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. *Psychosomatics* 50:78-86.
- 97) Pae CU, Masand PM, Peindl K, Han C, Marks D, Patkar AA (2008) An open label, rater-blinded, flexible-dose, 8-week trial of escitalopram in major depressive disorder. *Prim Care Companion J Cl Psych*. 10:205-210.
- 98) Pae CU, Masand PS, Peindl K, Mannelli P, Han C, Marks DM, Patkar AA (2008) An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features. *Prim Care Companion J Clin Psychiatry* 10:205-210
- 99) Pae CU, Yu HS, Amann D, Kim JJ, Lee CU, Lee SJ, Jun TY, Lee C, Paik IH, Patkar AA, Lerer B (2008) Association of the trace amine associated receptor 6 (TAAR6) gene with schizophrenia and bipolar disorder in a Korean case control sample. *J Psychiatr Res*. 42:35-40
- 100) Pae CU, Lim HK, Peindl K, Ajwani N, Serretti A, Patkar AA, Lee C (2008) The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. *Int Clin Psychopharmacol*. 23:1-8.

- 101) Pae CU, Serretti A, Patkar AA, Masand PS (2008) Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. *CNS Drugs* 22:367-88.
- 102) Pae CU, Han C, Marks DM, Patkar AA (2008) Comments on “Addition of lamotrigine to valproic acid: a successful outcome in a case of rapid-cycling bipolar affective disorder”. *Prog Neuropsychopharmacol Biol Psychiatry* 32:595-596.
- 103) Pae CU, Marks DC, Han C, Patkar AA, Masand PS (2008) Duloxetine: An emerging evidence for fibromyalgia. *Biomed Pharmacother.* 63:69-71
- 104) Pae CU, Marks DM, Han C, Patkar AA (2008) A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression: Is there differential effect of ropinirole dose on developing psychotic symptom? *Prog Neuropsychopharmacol Biol Psychiatry.* 32:1087-1088.
- 105) Pae CU, Marks DM, Han C, Patkar AA, Masand P (2008) Delirium: where do we stand? *Curr Psychiatry Rep.:* 10:240-248.
- 106) Pae CU, Marks DM, Han C, Patkar AA (2008) Does minocycline have antidepressant effect? *Biomed Pharmacother.:* 62:308-311.
- 107) Pae CU, Drago A, Kim JJ, Patkar AA, Jun TY, Lee C, Mandelli L, De Ronchi D, Paik IH, Serretti A (2008) TAAR6 variation effect on clinic presentation and outcome in a sample of schizophrenic in-patients: An open label study. *Eur Psychiatry* 23:390-395.
- 108) Pae CU, Luyten P, Marks DM, Han C, Park SH, Patkar AA, Masand PS, Van Houdenhove B (2008) The relationship between fibromyalgia and major depressive disorder: a comprehensive review. *Curr Med Res Opin.* 24:2359-2371
- 109) Pae CU, Drago A, Kim JJ, Patkar AA, Jun TY, Lee C, Mandelli L, De Ronchi D, Paik IH, Serretti A (2008) DTNBP1 haplotype influences baseline assessment scores of schizophrenic in-patients. *Neurosci Lett.* 40:150-154.
- 110) Pae CU, Marks DM, Han C, Patkar AA, Masand P (2008) Delirium: Underrecognized and Undertreated. *Curr Treat Options Neurol.* 10:386-395.
- 111) Pae CU, Mandelli L, Han C, Ham BJ, Masand PS, Patkar AA, Steffens DC, De Ronchi D, Serretti A (2008) Do estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women. *Neuro Endocrinol Lett.* 29:500-506.
- 112) Pae CU, Marks DM, Han C, Patkar AA, Steffens D (2008) Does neurotrophin-3 have a therapeutic implication in major depression? *Int J Neurosci.* 118(11):1515-1522.
- 113) Pae CU, Marks DM, Han C, Patkar AA (2008) A case of transient hallucination with ropinirole augmentation in a patient with treatment-resistant depression: is there differential effect of ropinirole dose on developing psychotic symptoms? *Progress in Neuropsychopharmacology and Biological Psychiatry* 15;32(4).
- 114) Pae CU, Mandelli L, Kim TS, Han C, Masand PS, Marks DM, Patkar AA, Steffens DC, De Ronchi D, Serretti A (2008) Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: A pilot study on differential effects of sex hormones on antidepressant effects. *Biomed Pharmacother.* Epub ahead of print.
- 115) Patkar AA, Mannelli P, Peindl K, Hill KP, Wu LT, Lee T, Kuhn C (2008) Relationship of the serotonin transporter with prolactin response to meta-chlorophenylpiperazine in cocaine dependence. *J Psychiatr Res.* 42:1213-1219

- 116) Wu LT, Pilowsky DJ, Patkar AA. (2008) Non-prescribed use of pain relievers among adolescents in the United States. *Drug Alcohol Depend.* 94:1-11.
- 117) Wu LT, Blazer DG, Stitzer ML, Patkar AA, Blaine JD (2008) Infrequent illicit methadone use among stimulant-using patients in methadone maintenance treatment programs: a national drug abuse treatment clinical trials network study. *Am J Addict.* 17:304-311.
- 118) Wu LT, Ringwalt CL, Mannelli P, Patkar AA. (2008) Prescription Pain Reliever Abuse and Dependence Among Adolescents: A Nationally Representative Study. *J Am Acad Child Adolesc Psychiatry* 47:1020-1029.
- 119) Wu LT, Ringwalt CL, Mannelli P, Patkar AA (2008) Hallucinogen use disorders among adult users of MDMA and other hallucinogens. *Am J Addict.* 17:354-363.
- 120) Leone FT, Skrzypczak JL, Everyys-Casey S, Weibel SB, Patkar AA. An empiric typology of the substages during the action stage of behavioral change during guided smoking cessation attempt. *Nicotine and Tobacco Research.* In press
- 121) Han C, Masand PS, Krulewicz S, Peindl K, Mannelli P, Varia IM, Pae CU, Patkar AA (2009) Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. *J Clin Pharm Ther.* 34:79-88.
- 122) Masand PS, Pae CU, Krulewicz S, Peindl K, Mannelli P, Varia I, Patkar AA. (2009) A randomized, double-blind, placebo-controlled trial of controlled release paroxetine in Irritable Bowel Syndrome. *Psychosomatic Medicine.* 120:448-454.
- 123) Pae CU, Park MH, Marks DM, Han C, Patkar AA, Masand PS. (2009) Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. *Curr Opin Investig Drugs* 10:75-90.
- 124) Pae CU, Marks DM, Han C, Masand PS, Patkar AA (2009) Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study. *Int Clin Psychopharmacol.* 24:29-33.
- 125) Pae CU, Mandelli L, De Ronchi D, Kim JJ, Jun TY, Patkar AA, Serretti A (2009) Dysbindin gene (DTNBP1) and Schizophrenia in Korean population. *Eur Arch Psychiatry Clin Neurosci.* 259(3):137-42.
- 126) Mannelli P, Patkar AA, Peindl K, Gottheil E, Wu LT, Gorelick DA. (2009) Early outcomes following low dose Naltrexone enhancement of opioid detoxification. *Am J Addict* 18(2):109-16.
- 127) Pae CU, Patkar AA, Masand PS (2009) Augmentation of dopaminergic agents for major depressive disorder. *J Clin Psychiatry* 70(3):432-3.
- 128) Wu LT, Blazer DG, Patkar AA, Stitzer ML, Wakim PG, Brooner RK (2009) Heterogeneity of stimulant dependence: a national drug abuse treatment clinical trials network study. *Am J Addict* 18(3):206-18.
- 129) Leone FT, Evers-Casey S, Veloski J, Patkar AA, Kanzleiter L, Pennsylvania continuum of tobacco education work shop (2009) Short-, intermediate-, and long-term outcomes of Pennsylvania's continuum of tobacco education pilot project. *Nicotine Tob Res.* 11(4):387-93.
- 130) Wu LT, Parrott AC, Ringwalt CL, Patkar AA, Mannelli P, Blazer DG (2009) The high prevalence of substance use disorders among recent MDMA users compared with other drug users: Implications for intervention. *Addict Behav.* 34(8):654-61.

- 131) Wu LT, Pan JJ, Blazer DG, Tai B, Stitzer ML, Brooner RK, Woody GE, Patkar AA, Blaine JD (2009) An item response theory modeling of alcohol and marijuana dependences: a National Drug Abuse Treatment Clinical Trials Network Study. *J Stud Alcohol Drugs*. 70(3):414-25.
- 132) Pae CU, Masand PS, Marks DM, Krulewicz S, Han C, Peindl K, Mannelli P, Patkar AA (2009) History of early abuse as a predictor of treatment response in patients with fibromyalgia: post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. *World J Biol Psychiatry*. 10(4 Pt 2):435-41.
- 133) Wu LT, Pan JJ, Blazer DG, Tai B, Brooner RK, Stitzer ML, Patkar AA, Blaine JD (2009) The construct and measurement equivalence of cocaine and opioid dependences: a National Drug Abuse Treatment Clinical Trials Network (CTN) study. *Drug Alcohol Depend*. 1;103(3):114-23.
- 134) Pae CU, Masand PS, Marks DM, Krulewicz S, Peindl K, Mannelli P, Patkar AA (2009) History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia. *Prog Neuropsychopharmacol Biol Psychiatry*. 31;33(6):996-1002.
- 135) Pae CU, Marks DM, Masand PS, Peindl K, Hooper-Wood C, Han C, Mannelli P, Ciccone P, Patkar AA (2009) Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trial. *Clin Neuropharmacol*. 32(2):85-8.
- 136) Pae CU, Marks DM, Patkar AA, Masand PS, Luyten P, Serretti A (2009) Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. *Expert Opin Pharmacother*. 10(10):1561-70.
- 137) Pae CU, Mandelli L, Han C, Ham BJ, Masand PS, Patkar AA, Steffens DC, De Ronchi D, Serretti A (2009) Thyroid hormones affect recovery from depression during antidepressant treatment. *Psychiatry Clin Neurosci*. 63(3):305-13.
- 138) Pae CU, Drago A, Forlani M, Patkar AA, Serretti A (2009) Investigation of an epistatic effect between a set of TAAR6 and HSP-70 genes variations and major mood disorders. *Am J Med Genet B Neuropsychiatr Genet*.
- 139) Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, Patkar A, Publicker M, McCain K, Potter JS, Forman R, Vetter V, McNicholas L, Blaine J, Lynch KG, Fudala P. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. *JAMA*. 2008 Nov 5;300(17):2003-11. Erratum in: *JAMA*. 2009 Feb 25;301(8):830.
- 140) Yun DH, Pae CU, Drago A, Mandelli L, De Ronchi D, Patkar AA, Paik IH, Serretti A, Kim JJ. Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder. *Psychiatry Investig*. 2008 Jun;5(2):102-5. Epub 2008 Jun 30.
- 141) Pae CU, Serretti A, Patkar AA, Masand PS. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. *CNS Drugs*. 2008;22(5):367-88.
- 142) Patkar AA, Mannelli P, Peindl K, Hill KP, Wu LT, Lee T, Kuhn C. Relationship of the serotonin transporter with prolactin response to meta-chlorophenylpiperazine in cocaine dependence. *J Psychiatr Res*. 2008 Oct;42(14):1213-9. Epub 2008 Mar 5.
- 143) Wu LT, Pilowsky DJ, Patkar AA. Non-prescribed use of pain relievers among adolescents in the United States. *Drug Alcohol Depend*. 2008 Apr 1;94(1-3):1-11. Epub 2007 Dec 3.
- 144) Pae CU, Marks DM, Shah M, Han C, Ham BJ, Patkar AA, Masand PS (2009) Milnacipran: beyond a role of antidepressant. *Clin Neuropharmacol*. 32(6):355-63.

- 145) Pae CU, Drago A, Patkar AA, Jun TY, Serretti A (2009) Epistasis between a set of variations located in the TAAR6 and HSP-70 genes toward schizophrenia and response to antipsychotic treatment. *Eur Neuropsychopharmacol*. 19(11):806-11.
- 146) Patkar AA, Rozen S, Mannelli P, Matson W, Pae CU, Krishnan KR, Kaddurah-Daouk R (2009) Alterations in tryptophan and purine metabolism in cocaine addiction: a metabolomic study. *Psychopharmacology (Berl)*. 206(3):479-89.
- 147) Wu LT, Ringwalt CL, Patkar AA, Hubbard RL, Blazer DG (2009) Association of MDMA/ecstasy and other substance use with self-reported sexually transmitted diseases among college-aged adults: a national study. *Public Health*. 123(8):557-64.
- 148) Mannelli P, Patkar AA, Rozen S, Matson W, Krishnan R, Kaddurah-Daouk R. (2009) Opioid use affects antioxidant activity and purine metabolism: preliminary results. *Hum Psychopharmacol*. 24(8):666-75.
- 149) Langley PC, Patkar AA, Boswell KA, Benson CJ, Schein JR. (2010) Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain. *Curr Med Res Opin*. 26(1):239-51.
- 150) Pae CU, Tharwani H, Marks DM, Masand PS, Patkar AA. (2009) Atypical depression: a comprehensive review. *CNS Drugs*. 1;23(12):1023-37.
- 151) Han C, Pae CU, Patkar AA, Masand PS, Kim KW, Joe SH, Jung IK (2009) Psychometric properties of the patient Health Questionnaire- 15 (PHQ-15) for measuring the somatic symptoms of psychiatric outpatients. *Psychosomatics*. 50(6):580-5.
- 152) Marks DM, Patkar AA, Masand PS, Pae CU. (2009) Does pregabalin have neuropsychotropic effects?: a short perspective. *Psychiatry Investig*. 6(2):55-8.
- 153) Pae CU, Misra A, Ham BJ, Han C, Patkar AA, Masand PS. (2010) Paroxetine mesylate: comparable to paroxetine hydrochloride? *Expert Opin Pharmacother*. 11(2):185-93.
- 154) Seo HJ, Sohi MS, Patkar AA, Masand PS, Pae CU. (2010) Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms. *Postgrad Med*. 122(1):125-38.
- 155) Patkar AA, Bhatia K, Lee J (2009) Diagnosis and Treatment of Opioid Dependence (2009) *BMJ Point of Care* 224: 14-19.
- 156) Ling W, Casadonte P, Bigelow G, Kampman KM, Patkar AA, Bailey GL, Rosenthal RN, Beebe KL. (2010) Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. *JAMA*. 2010 Oct 13;304(14):1576-83.
- 157) Kane JM, D'Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RS. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. *J Clin Psychiatry*. 2010 Nov;71(11):1475-81. Epub 2010 Aug 24.
- 158) Mannelli P, Peindl K, Patkar AA, Wu LT, Pae CU, Gorelick DA. Reduced cannabis use after low-dose naltrexone addition to opioid detoxification. *J Clin Psychopharmacol*. 2010 Aug;30(4):476-8.
- 159) Patkar AA, Li TK. Treatments for alcohol dependence: rethinking the role of comorbidity and clinical subtypes. *Am J Psychiatry*. 2010 Jun;167(6):620-2.
- 160) Pae CU, Drago A, Kim JJ, Patkar AA, Jun TY, De Ronchi D, Serretti A. TAAR6 variations possibly associated with antidepressant response and suicidal behavior. *Psychiatry Res*. 2010 Nov 30;180(1):20-4. Epub 2010 May 21.

- 161) Meade CS, Weiss RD, Fitzmaurice GM, Poole SA, Subramaniam GA, Patkar AA, Connery HS, Woody GE. HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study. *J Acquir Immune Defic Syndr*. 2010 Sep 1;55(1):65-72.
- 162) Pae CU, Sohi MS, Seo HJ, Serretti A, Patkar AA, Steffens DC, Masand PS. Quetiapine XR: current status for the treatment of major depressive disorder. *Prog Neuropsychopharmacol Biol Psychiatry*. 2010 Oct 1;34(7):1165-73. Epub 2010 Mar 20. Review.
- 163) Pae CU, Chiesa A, Mandelli L, Patkar AA, Gibiino S, Serretti A. Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study. *Clin Drug Investig*. 2010;30(3):187-93. doi: 10.2165/11533060-000000000-00000.
- 164) Seo HJ, Sohi MS, Patkar AA, Masand PS, Pae CU. Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms. *Postgrad Med*. 2010 Jan;122(1):125-38. Review.
- 165) Pae CU, Misra A, Ham BJ, Han C, Patkar AA, Masand PS. Paroxetine mesylate: comparable to paroxetine hydrochloride? *Expert Opin Pharmacother*. 2010 Feb;11(2):185-93. Review.
- 166) Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. *CNS Drugs*. 2011 Feb 1;25(2):109-27. doi: 10.2165/11538980-000000000-00000.
- 167) Seo HJ, Chiesa A, Lee SJ, Patkar AA, Han C, Masand PS, Serretti A, Pae CU. Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications. *Clin Neuropharmacol*. 2011 Jan-Feb;34(1):39-47.
- 168) Pae CU, Drago A, Forlani M, Patkar AA, Serretti A. Investigation of an epistatic effect between a set of TAAR6 and HSP-70 genes variations and major mood disorders. *Am J Med Genet B Neuropsychiatr Genet*. 2010 Mar 5;153B(2):680-3.
- 169) Lee SY, Park MH, Patkar AA, Pae CU. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. *Prog Neuropsychopharmacol Biol Psychiatry*. 2010 Dec 10. [Epub ahead of print]
- 170) Serretti A, Chiesa A, Porcelli S, Han C, Patkar AA, Lee SJ, Park MH, Pae CU. Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. *Psychiatry Res*. 2011 Mar 9. [Epub ahead of print]
- 171) Pae CU, Koh JS, Lee SJ, Han C, Patkar AA, Masand PS. Association of sedative-hypnotic medications with suicidality. *Expert Rev Neurother*. 2011 Mar;11(3):345-9.
- 172) Paulozzi LJ, Weisler RH, Patkar AA. A national epidemic of unintentional prescription opioid overdose deaths: how physicians can help control it. *J Clin Psychiatry*. 2011 Apr 19. [Epub ahead of print]
- 173) Manelli P, Peindl K, Patkar AA, Wu LT, Tharwani HM, Gorelick DA. Problem drinking and low-dose naltrexone-assisted opioid detoxification. *J Stud Alcohol Drugs*. 2011 May;72(3):507-13.

Nonrefereed publications:

- 1) Patkar AA & Shah LP (1989) Chronic Depression - Concept and Contributing factors. *Bombay Hospital Journal* 31:93-98.

- 2) Patkar AA & Shah LP (1990) Chronic Depression - Strategies of Management. *Bombay Hospital Journal* 32:79-85.
- 3) Hill KP, Patkar AA, Weinstein SP (2001) Folie a famille associated with amphetamine use. *Jefferson Journal of Psychiatry* 16:26-31.

3. Book Chapters

1. Masand PS, Christopher E, Clary GS, Mago RM, Patkar AA, (2004) Mania, Catatonia, & Psychosis in the Medically Ill. In *Textbook of Consultation-Liaison Psychiatry*, American Psychiatric Press, Washington DC.
2. Pae Chi-un and Patkar AA (2008) Neuropharmacology of Anxiety Disorders. In *Pharmacology and Therapeutics. From Principles to Practice* (Eds Waldman SA and Terzic A) , Elsevier, NY.

4. Others (Abstracts)

Selected Abstracts from over 250 scientific presentations at national and international conferences. Abstracted in the proceedings of the meetings.

- 1) *Plasma serotonin levels and craving in alcohol withdrawal.* Patkar AA, Naik PC, McLean PC, Foster D, Al-Chawabi T, Marsden C, Summer meeting of the British Association of Psychopharmacology and Interdisciplinary Society for Biological Psychiatry, Cambridge- July 1994.
- 2) *Trends in substance use among schizophrenic subjects :1984-1994.* Patkar AA, Alexander RC, Certa KM and Boardman C American Psychiatric Association Annual Conference, New York - May 1996.
- 3) *Medical symptoms in alcohol, cocaine and heroin abusers.* Patkar AA, Gottheil E, Sterling RC et al. American Psychiatric Association Annual Conference, San Diego, California - May 1997.
- 4) *Tobacco smoking and medical symptoms among cocaine abusers* Patkar AA, Lundy A, Weinstein SP and Serota R., Annual Conference of the American Society of Addiction Medicine, New York, April 1999.
- 5) *Cigarette smoking and negative symptoms in schizophrenia.* Patkar AA, Certa KM, Lundy A, Weinstein SP and Vergare MJ. American Psychiatric Association Annual Conference, Washington D.C. - May 1999.
- 6) *Changes in psychological responses to m-CPP among cocaine dependent patients and controls.* Patkar AA, Gottheil E, Berrettini WH, Sterling RC, Weinstein SP and Serota R. American Psychiatric Association Annual Conference, Washington D.C. - May 1999.
- 7) *A comparison of nicotine dependence among cocaine and opiate abusers.* Patkar AA, Lundy A, Demaria P, Leone F, Purcell C and Weinstein SP. Annual meeting of the Society for research on nicotine and tobacco, Arlington Virginia, February, 2000.
- 8) *Cigarette smoking among medical students: Comparison across class years.* Patkar AA, Hill K, Lundy A, Purcell C and Weinstein SP. Annual Conference of the American Society of Addiction Medicine, Chicago, April 2000.
- 9) *Mu opiate receptor changes on blood cells from opiate abusers* Patkar, AA, Zeiger AR, Lundy A, Weinstein SP. Royal College of Psychiatrists Annual Meeting Edinburgh, Scotland July 2000.
- 10) *Serum prolactin levels and treatment outcome among cocaine dependent patients.* Patkar AA, Hill K, Sterling RC, Gottheil E, Weinstein SP. American Psychiatric Association Institute on Services meeting, Philadelphia October, 2000.
- 11) *Relationship between serum prolactin and response to treatment in cocaine dependence.* Hill K, Patkar AA, Sterling RC, Gottheil E, Weinstein SP. American Academy of Addiction Psychiatry meeting, Amelia Island, Florida, December, 2000.
- 12) *Attitudes of pennsylvania voters regarding statewide tobacco policy.* Leone FT, Batra V, Patkar AA et al., annual meeting of the Society for research on nicotine and tobacco, Seattle, Washington, March, 2001.

- 13) *Polymorphism in the 5HT Transporter Gene and cocaine dependence.* Patkar, AA, Berrettini, WH, Gottheil E, Wendel B, Sterling RC, and Weinstein SP. American Psychiatric Association Annual Conference, New Orleans, Louisiana. - May 2001.
- 14) *Relationship between opioid use, opioid receptor densities and erythrocyte properties among heroin abusers.* Patkar, AA, Zeiger A, Lundy A, & Weinstein SP Annual Scientific Meeting of the College on Problems of Drug Dependence, June, 2001
- 15) *Impact of structure and funding on an integrated bio-behavioral approach to smoking cessation.* Meier B, Leone F, Patkar A, Weibel S, Batra V, Pollice M, Purcell C, Weinstein S, Steinberg M. American Lung Society Annual Meeting, Philadelphia, PA, November 2001.
- 16) *A comparison of pre-treatment characteristics and treatment-outcome for alcohol-, cocaine- and multisubstance-dependent individuals.* Hill KP, Patkar AA, Thornton CC, Gottheil E, Weinstein SP American Academy of Addiction Psychiatry meeting, Amelia Island, Florida, December, 2001.
- 17) *Tobacco smoking and treatment-outcome among African-American cocaine dependent patients* Patkar AA, Leone F, Purcell, CP, Weibel S, Weinstein SP annual meeting of the Society for research on nicotine and tobacco, Savannah, Georgia, March, 2002.
- 18) *Predicting treatment-outcome in cocaine dependence from admission urine drug screen and peripheral serotonergic measures.* Hill KP, Patkar AA, Thornton CC, Berrettini, WH, Gottheil E, Weinstein SP Annual Conference of the American Society of Addiction Medicine, Atlanta, Georgia April 2002.
- 19) *Platelet Serotonin uptake, impulsivity and treatment-outcome among African-American cocaine abusers.* Patkar AA, Gottheil E, Berrettini, Weinstein SP, Vergare MJ. American Psychiatric Association Research Colloquium for junior investigators, Philadelphia, PA, May 2002.
- 20) *Relationship between platelet serotonin uptake sites and measures of impulsivity, aggression and sensation seeking among cocaine abusers.* Patkar AA, Gottheil E, Berrettini, WH, Hill KP, Weinstein SP (2001) American Psychiatric Association Annual Conference, Philadelphia, PA, May 2002.
- 21) *Platelet Tritiated Paroxetine Binding and Treatment Outcome among African-American Cocaine Dependent Individuals.* Patkar AA, Gottheil E, Berrettini, WH, Hill KP, Weinstein SP (2002) American Psychiatric Association Annual Conference, Philadelphia, PA, May 2002.
- 22) *Tobacco use following treatment for crack cocaine dependence in men and women* Lundy A, Patkar AA, Crawford KA. 9th Annual meeting of the Society for Research in Nicotine and Tobacco , New Orleans, Louisiana, Feb 2003.
- 23) *Relationship of nicotine dependence with sensation seeking and aggression among African-American healthy volunteers and cocaine abusers.* Murray HW, Patkar AA, Desai A, Batra V, Leone FT. 9th Annual meeting of the Society for Research in Nicotine and Tobacco , New Orleans, Louisiana, February 2003.
- 24) *Medical symptoms associated with tobacco smoking with and without marijuana abuse among crack cocaine dependent patients.* Purcell C, Patkar AA, Batra V, Mannelli P, Evers-Casey S, Leone FT. 9th Annual meeting of the Society for Research in Nicotine and Tobacco , New Orleans, Louisiana, February 2003.
- 25) *Smoking habits among medical and nursing students.* Evers-Casey S, Patkar AA, Purcell S, Batra V, Leone FT. 9th Annual meeting of the Society for Research in Nicotine and Tobacco , New Orleans, Louisiana, February 2003.
- 26) *Differences in platelet serotonin transporter sites between African-American Tobacco smokers and Nonsmokers.* Patkar AA, Gopalakrishnan R, Murray HW, Berrettini WH, Leone FT. 9th Annual meeting of the Society for Research in Nicotine and Tobacco , New Orleans, Louisiana, February 2003.
- 27) *Pre-treatment measures of impulsivity, aggression and sensation-seeking predict treatment-outcome for African-American Cocaine Dependent Individuals.* Murray HW, Patkar AA, Gopalakrishnan R, Desai AM, Vergare MJ American Psychiatric Association Annual Conference, San Francisco, CA, May 2003.
- 28) *Relationship between serotonin transporter gene polymorphisms and platelet serotonin transporter sites among African-American cocaine dependent individuals and healthy volunteers.* Bilal, L, Patkar AA, Berrettini WH, Mannelli P, Vergare MJ. American Psychiatric Association Annual Conference, San Francisco, CA, May 2003.

- 29) *Differences in peripheral noradrenergic function in actively drinking and recently abstinent alcohol-dependent individuals.* Desai AM, Patkar AA, Gopalakrishnan R, Vergare MJ, Weinstein SP American Psychiatric Association Annual Conference, San Francisco, CA, May 2003.
- 30) *Changes in noradrenaline and serotonin levels and craving during alcohol withdrawal.* Patkar AA, Gopalakrishnan R, Murray HW, Desai AM, Vergare MJ, Weinstein SP American Psychiatric Association Annual Conference, San Francisco, CA, May 2003.
- 31) *Predictors of Response to a Placebo-Controlled, Double-Blind Trial of Paroxetine Controlled Release in Fibromyalgia* Purcell C, Peindl K, Krulewicz S, Dube E, Jiang W, Masand PS, Patkar AA. American Psychiatric Association Annual Conference, New York, NY, May 2004.
- 32) *Paroxetine Controlled Release in the Treatment of Irritable Bowel Syndrome* Masand PS, Alamy S, Varia S, Mattila-Evenden M, Krulewicz S, Dube E, Patkar AA. American Psychiatric Association Annual Conference, New York, NY, May 2004.
- 33) *Aripiprazole as an Augmentation Agent in Treatment-Resistant Depression* Bilal L, Masand P, Mattila-evenden M, Peindl K, Patkar AA. American Psychiatric Association Annual Conference, New York, NY, May 2004.
- 34) *Relationship of Serotonin Transporter Polymorphism to Treatment Outcome in Cocaine Dependence* M. Mattila-Evenden M, Berrettini WH, Murray HW, Bilal L, Peindl K, Mannelli P, Patkar AA. American Psychiatric Association Annual Conference, New York, NY, May 2004.
- 35) *Mediators of Depression as a Predictor of Outcome in Cocaine Dependence* Mago R, Murray HW, Gottheil E, Vergare M, Mannelli, P, Thornton CC, Patkar AA. American Psychiatric Association Annual Conference, New York, NY, May 2004
- 36) *Tobacco Smoking Following Treatment for Cocaine Dependence* Murray HW, Leone FT, Vergare M, Mannelli, P, Peindl, K, Patkar AA. American Psychiatric Association Annual Conference, New York, NY, May 2004.
- 37) *Prolactin, Severity of Drug Use, and Treatment Outcome in Cocaine Dependence.* Frey AC, Berrettini WH, Murray HW, M. Mattila-Evenden M, Vergare M, Mannelli P. Patkar AA. American Psychiatric Association Annual Conference, New York, NY, May 2004.
- 38) *History of depressive and anxiety disorders as predictors of response in Fibromyalgia.* Patkar AA, Peindl K, Krulewicz S, Jiang W, Mannelli P, Masand PS. American Psychiatric Association Annual Conference, Atlanta, GA, May 2005.
- 39) *Personality profiles as predictors of response for fibromyalgia* Murray H, Patkar AA, Peindl K, Krulewicz S, Dube E, Masack P. American Psychiatric Association Annual Conference, Atlanta, GA, May 2005.
- 40) *Mediators of Depression as a Predictor for Outcome of Treatment in Cocaine-Dependent Patients.* Patkar AA, Mago R, Mannelli P, Peindl K. American Psychiatric Association Annual Conference, Atlanta, GA, May 2005.
- 41) *A randomized, double-blind, placebo-controlled, flexible-dose, trial of augmentation with OROS methylphenidate in treatment resistant depression* Masand PS, Peindl K, Hooper-Wood C, Ciccone PE, Pae C, Mannelli P, Patkar AA American Psychiatric Association Annual Conference, Toronto, ON, Canada, May 2006
- 42) *A Randomized, Double-Blind, Placebo-Controlled Trial of Sodium Oxybate in Fibromyalgia Syndrome [FMS].* Patkar AA, Bennett R, Michalek J, Cook H, Perera P, Masand P. American Psychiatric Association Annual Conference, Toronto, ON, Canada, May 2006
- 43) *Sexual abuse, health status and treatment response to Paroxetine controlled release (CR) in fibromyalgia.* Patkar AA, Peindl K, Krulewicz S, Mannelli P, Pae C, Masand P. American Psychiatric Association Annual Conference, San Diego, CA, May 2007.
- 44) *Childhood Abuse History as a Predictor of Treatment Response in Patients with Irritable Bowel Syndrome : A Post-hoc Analysis of a 12-week, Randomized, Double-blind, Placebo-Controlled Trial of Paroxetine CR.* Pae C, Masand P, Peindl K, Krulewicz S, Han C, Mannelli P, Varia I, Patkar AA. American Psychiatric Association Annual Conference, San Diego, CA, May 2007.

- 45) *An Open label, rater-blinded, 6-week trial of escitalopram in major depression with atypical features* Ajwani N, Pae C, Masand P, Piendl K, Mannelli P, Patkar AA American Psychiatric Association Annual Conference, San Diego, CA, May 2007
- 46) *Has the Quality of Clinical Trials Reporting in Psychiatry improved after CONSORT Guidelines?* Han C, Pae C, Bhatia K, Marks D, Oguejiofor C, Masand P, Patkar AA American Psychiatric Association Annual Conference, Washington, NC, May 2008.
- 47) *Patient Satisfaction with a Telemedicine-based evaluation in an Addiction Treatment Program.* Matthew R, Hubbard R, House K, Peindl K, Youkins M, Patkar AA American Psychiatric Association Annual Conference, Washington, NC, May 2008
- 48) *Trends in non-heroin opioid abuse admissions in the U.S.* Gopalakrishnan R, Peindl K, Mannelli P, Beebe K, Patkar AA. American Psychiatric Association Annual Conference, Washington, DC, May 2008
- 49) *Screening and Brief Interventions for underage drinkers in underserved populations.* Patkar AA, Kemper A, Dolor R, Anderson J, Thanaseelan J, Robinson L, Peindl K, Hubbard R. American Psychiatric Association Annual Conference, San Francisco, May 2009
- 50) *Effects of adjunctive treatment with armodafinil in schizophrenia.* Patkar AA, Kane JM, Keefe SE, Youakim JM, Tiller J, D'Souza DC American Psychiatric Association Annual Conference, San Francisco, May 2009

PRESENTATIONS &
INVITED LECTURES:

Over 300 (details available on request).

Selected presentations

1. *Platelet imipramine binding in alcohol dependents.* Patkar AA et al, Summer meeting of the British Association of Psychopharmacology and Interdisciplinary Society for Biological Psychiatry, Cambridge- July 1994.
2. *Plasma serotonin levels and craving in alcohol withdrawal.* Patkar AA et al, Summer meeting of the British Association of Psychopharmacology and Interdisciplinary Society for Biological Psychiatry, Cambridge- July 1994.
3. *Evaluation of the Nottingham Methadone Maintenance program using measures of outcome.* Patkar AA McLean PC, Melville R, et al AMERSA conference, Washington DC- September 1995.
4. *Raising the profiles of Substance Abuse and Alcoholism.* Invited Speaker Workshop Organized by Institute of Medicine, Washington DC - May 1996.
5. *Trends in substance use among schizophrenic subjects :1984-1994.* Patkar AA, Alexander RC, Certa KM and Boardman C American Psychiatric Association Annual Conference, New York - May 1996.
6. *Medical symptoms in alcohol, cocaine and heroin abusers.* Patkar AA, Gottheil E, Sterling RC et al. American Psychiatric Association Annual Conference, San Diego, California - May 1997.
7. *Cocaine use and negative symptoms in schizophrenia.* Patkar AA, Alexander RC, Certa KM and Lundy A Regional Meeting of the World Psychiatric Association, Jaipur, India-January 1998.
8. *Detoxification and treatment regimen for drug addiction.* Invited speaker at Symposium at the Regional Meeting of the World Psychiatric Association, Jaipur, India-January 1998.
9. *Cocaine & other stimulants* Brown Bag lecture series, Thomas Jefferson University, February 1998.
10. *Comparison of hair analysis, urine analysis & self-report in a cocaine treatment outcome study.* Hill KP, Lundy A & Patkar AA, Sigma XI Student research day, Philadelphia- March 1998.
11. *Environmental stimuli and psychophysiological aspect of panic disorder.* Mindlin G, Patkar AA et al. American Psychiatric Association Annual Conference, Toronto, Canada - May 1998.
12. *A comparison of medical symptoms and tobacco smoking among alcohol, heroin and cocaine abusers.* Patkar AA, Gottheil E, Sterling RC and Weinstein SP. Annual Nicotine Dependence Conference, American Society of Addiction Medicine, Marina Del Rey, California - November 1998
13. *Nicotine dependence and tobacco smoking. Where do we stand today?* *Brown Bag Lecture Series*, Thomas Jefferson University, February 1999.
14. *Serotonin transporter gene polymorphisms in cocaine dependence* Hill KP, Patkar AA, Berrettini WH, Gottheil E, Wendel B, Sterling RC and Weinstein SP AMIS-PHL Student Poster Competition, Philadelphia- April 1999.
15. *Crack smoking v/s tobacco smoking after cocaine treatment.* Lundy A, Patkar AA and Weinstein SP, Annual Conference of the Society for Research on Nicotine and Tobacco, San Diego, California, March 1999.

16. *Characteristics of smokers and nonsmokers among drug abusers.* Lundy A, Patkar AA and Weinstein SP, Annual Conference of the Society for Research on Nicotine and Tobacco, San Diego, California, March 1999.
17. *Tobacco smoking and medical symptoms among cocaine abusers* Patkar AA, Lundy A, Weinstein SP and Serota R., Annual Conference of the American Society of Addiction Medicine, New York, April 1999.
18. *Severe nicotine dependency and tobacco use in medical outpatients.* Sambandam K, Patkar AA, Steinberg M, Weibel S, Weinstein SP, and Leone FT (1999) International meeting of the American Thoracic Society, San Diego, California, April 1999.
19. *ECT in the presence of increased intracranial pressure: Evaluation and reduction of risk.* Hill K, Patkar AA, Weinstein SP and Schwartz SL, Annual meeting of the Association of Electroconvulsive Therapy, Washington DC, May 1999.
20. *Environmental stimuli and psychophysiological aspect of migraine.* Mindlin G, Patkar AA et al. American Psychiatric Association Annual Conference, Washington DC - May 1999.
21. *Serotonin transporter gene polymorphisms and cocaine dependence.* Patkar, AA, Berrettini, WH, Gottheil E, Wendel B, Sterling RC, and Weinstein SP. American Psychiatric Association Annual Conference, Washington D.C. - May 1999.
22. *Cigarette smoking and negative symptoms in schizophrenia.* Patkar AA, Certa KM, Lundy A, Weinstein SP and Vergare MJ. American Psychiatric Association Annual Conference, Washington D.C. - May 1999.
23. *Changes in psychological responses to m-CPP among cocaine dependent patients and controls.* Patkar AA, Gottheil E, Berrettini WH, Sterling RC, Weinstein SP and Serota R. American Psychiatric Association Annual Conference, Washington D.C. - May 1999.
24. *Attempt to quit smoking among substance abusers.* Lundy A, Patkar AA, Leone F, Meier B and Weinstein SP. Annual meeting of the Society for research on nicotine and tobacco, Arlington Virginia, February, 2000.
25. *A comparison of nicotine dependence among cocaine and opiate abusers.* Patkar AA, Lundy A, Demaria P, Leone F, Purcell C and Weinstein SP. Annual meeting of the Society for research on nicotine and tobacco, Arlington Virginia, February, 2000.
26. *Elevated mu opioid receptor densities on blood cells from opiate abusers.* Zeiger AR, Patkar AA, Lundy AC. Annual Conference of the American Society of Addiction Medicine, Chicago, April 2000.
27. *Cigarette smoking among medical students: Comparison across class years.* Patkar AA, Hill K, Lundy A, Purcell C and Weinstein SP. Annual Conference of the American Society of Addiction Medicine, Chicago, April 2000.
28. *Changes in opiate receptors on blood cells from opiate abusers.* Patkar, AA, Zeiger AR, Lundy A, Weinstein SP American Psychiatric Association Annual Conference Chicago , May 2000.
29. *Mu opiate receptor changes on blood cells from opiate abusers* Patkar, AA, Zeiger AR, Lundy A, Weinstein SP. Royal College of Psychiatrists Annual Meeting Edinburgh, Scotland July 2000.
30. *A comparison of smoking habits between medical and nursing students.* Purcell C, Patkar AA, Weibel S, Lundy A. American Psychiatric Association Institute on Services meeting, Philadelphia October, 2000.
31. *Serum prolactin levels and treatment outcome among cocaine dependent patients.* Patkar AA, Hill K, Sterling RC, Gottheil E, Weinstein SP. American Psychiatric Association Institute on Services meeting, Philadelphia October, 2000.
32. *Relationship between serum prolactin and response to treatment in cocaine dependence.* Hill K, Patkar AA, Sterling RC, Gottheil E, Weinstein SP. American Academy of Addiction Psychiatry meeting, Amelia Island, Florida, December, 2000.
33. *Attitudes of pennsylvania voters regarding statewide tobacco policy.* Leone FT, Batra V, Patkar AA et al., annual meeting of the Society for research on nicotine and tobacco, Seattle, Washington, March, 2001.
34. *An integrated biobehavioral approach to smoking cessation: A tale of two treatments.* Meier, B, Leone FT, Purcell C, Patkar AA et al., annual meeting of the Society for research on nicotine and tobacco, Seattle, Washington, March, 2001.
35. *Medical symptoms and combined tobacco and marijuana use among drug abusers.* Lundy A, Patkar AA, Batra V, Leone F, Purcell C., annual meeting of the Society for research on nicotine and tobacco, Seattle, Washington, March, 2001.
36. *Serotonin transporter polymorphisms in cocaine dependence.* Hill KP, Patkar AA, Berrettini, WH, Gottheil E, Wendel B, Sterling RC, and Weinstein SP. Sigma XI Student research day, Philadelphia- March 2001.
37. *Red blood cell abnormalities among opiate abusers.* Zeiger AR, Fitzgerald R, Patkar AA, Ballas SK, Lundy A, Weinstein SP. Annual Conference of the American Society of Addiction Medicine, Los Angeles, CA April 2001.
38. *Polymorphism in the 5HT Transporter Gene and cocaine dependence.* Patkar, AA, Berrettini, WH, Gottheil E, Wendel B, Sterling RC, and Weinstein SP. American Psychiatric Association Annual Conference, New Orleans, Louisiana. - May 2001.
39. *New trends in the treatment of depression.* Patkar AA. Lecture given at Bombay India, Bergen Health Care, March 2001.
40. *Relationship between opioid use, opioid receptor densities and erythrocyte properties among heroin abusers.* Patkar, AA, Zeiger A, Lundy A, & Weinstein SP Annual Scientific Meeting of the College on Problems of Drug Dependence, June, 2001
41. *Behavioral manifestations of denial among cocaine users.* Lundy A, & Patkar AA Annual Scientific Meeting of the College on Problems of Drug Dependence, June, 2001.
42. *Impact of structure and funding on an integrated bio-behavioral approach to smoking cessation.* Meier B, Leone F, Patkar A, Weibel S, Batra V, Pollice M, Purcell C, Weinstein S, Steinberg M. American Lung Society Annual Meeting, Philadelphia, PA, November 2001.
43. *Are all tobacco control ads created equally? A qualitative study of teenager opinions regarding two different prevention messages.* Purcell C, Purcell N, Batra V, Weibel S, Patkar A, Leone F. American Lung Society Annual Meeting, Philadelphia, PA, November 2001.

44. *A comparison of pre-treatment characteristics and treatment-outcome for alcohol-,cocaine-and multisubstance-dependent individuals.* Hill KP, Patkar AA, Thornton CC, Gottheil E, Weinstein SP American Academy of Addiction Psychiatry meeting, Amelia Island, Florida, December, 2001.
45. *Tobacco smoking and treatment-outcome among African-American cocaine dependent patients* Patkar AA, Leone F, Purcell, CP, Weibel S, Weinstein SP annual meeting of the Society for research on nicotine and tobacco, Savannah, Georgia, March, 2002.
46. *Predicting treatment-outcome in cocaine dependence from admission urine drug screen and peripheral serotonergic measures.* Hill KP, Patkar AA, Thornton CC, Berrettini, WH, Gottheil E, Weinstein SP Annual Conference of the American Society of Addiction Medicine, Atlanta, Georgia April 2002.
47. *Platelet Serotonin uptake, impulsivity and treatment-outcome among African-American cocaine abusers.* Patkar AA, Gottheil E, Berrettini, Weinstein SP, Vergare MJ. American Psychiatric Association Research Colloquium for junior investigators, Philadelphia, PA, May 2002.
48. *Relationship between platelet serotonin uptake sites and measures of impulsivity, aggression and sensation seeking among cocaine abusers.* Patkar AA, Gottheil E, Berrettini, WH, Hill KP, Weinstein SP (2001) American Psychiatric Association Annual Conference, Philadelphia, PA, May 2002.
49. *Platelet Tritiated Paroxetine Binding and Treatment Outcome among African-American Cocaine Dependent Individuals.* Patkar AA, Gottheil E, Berrettini, WH, Hill KP, Weinstein SP (2002) American Psychiatric Association Annual Conference, Philadelphia, PA, May 2002.
50. *In-hospital bedside smoking cessation preferences among patients and nurses.* Alade F, Brawer R, Plumb J, Patkar AA, Leone F. American College of Chest Physicians International Meeting, May 2002.
51. *Attitudes and beliefs of physicians-in-training regarding nicotine addiction and treatment.* Khurana S, Batra V, Kim V, Patkar AA, Leone FT American College of Chest Physicians International Meeting, May 2002.
52. *Tobacco use following treatment for crack cocaine dependence in men and women* Lundy A, Patkar AA, Crawford KA. 9th Annual meeting of the Society for Research in Nicotine and Tobacco , New Orleans, Louisiana, Feb 2003.
53. *Relationship of nicotine dependence with sensation seeking and aggression among African-American healthy volunteers and cocaine abusers.* Murray HW, Patkar AA, Desai A, Batra V, Leone FT. 9th Annual meeting of the Society for Research in Nicotine and Tobacco , New Orleans, Louisiana, February 2003.
54. *Medical symptoms associated with tobacco smoking with and without marijuana abuse among crack cocaine dependent patients.* Purcell C, Patkar AA, Batra V, Mannelli P, Evers-Casey S, Leone FT. 9th Annual meeting of the Society for Research in Nicotine and Tobacco , New Orleans, Louisiana, February 2003.
55. *Smoking habits among medical and nursing students.* Evers-Casey S, Patkar AA, Purcell S, Batra V, Leone FT. 9th Annual meeting of the Society for Research in Nicotine and Tobacco , New Orleans, Louisiana, February 2003.
56. *Differences in platelet serotonin transporter sites between African-American Tobacco smokers and Nonsmokers.* Patkar AA, Gopalakrishnan R, Murray HW, Berrettini WH, Leone FT. 9th Annual meeting of the Society for Research in Nicotine and Tobacco , New Orleans, Louisiana, February 2003.
57. *Pre-treatment measures of impulsivity, aggression and sensation-seeking predict treatment-outcome for African-American Cocaine Dependent Individuals.* Murray HW, Patkar AA, Gopalakrishnan R, Desai AM, Vergare MJ American Psychiatric Association Annual Conference, San Francisco, CA, May 2003.
58. *Relationship between serotonin transporter gene polymorphisms and platelet serotonin transporter sites among African-American cocaine dependent individuals and healthy volunteers.* Bilal, L, Patkar AA, Berrettini WH, Mannelli P, Vergare MJ. American Psychiatric Association Annual Conference, San Francisco, CA, May 2003.
59. *Differences in peripheral noradrenergic function in actively drinking and recently abstinent alcohol-dependent individuals.* Desai AM, Patkar AA, Gopalakrishnan R, Vergare MJ, Weinstein SP American Psychiatric Association Annual Conference, San Francisco, CA, May 2003.
60. *Changes in noradrenaline and serotonin levels and craving during alcohol withdrawal.* Patkar AA, Gopalakrishnan R, Murray HW, Desai AM, Vergare MJ, Weinstein SP American Psychiatric Association Annual Conference, San Francisco, CA, May 2003.
61. *Predictors of Response to a Placebo-Controlled, Double-Blind Trial of Paroxetine Controlled Release in Fibromyalgia* Purcell C, Peindl K, Krulewicz S, Dube E, Jiang W, Masand PS, Patkar AA. American Psychiatric Association Annual Conference, New York, NY, May 2004.
62. *Paroxetine Controlled Release in the Treatment of Irritable Bowel Syndrome* Masand PS, Alamy S, Varia S, Mattila-Evenden M, Krulewicz S, Dube E, Patkar AA. American Psychiatric Association Annual Conference, New York, NY, May 2004.
63. *Aripiprazole as an Augmentation Agent in Treatment-Resistant Depression* Bilal L, Masand P, Mattila-evenden M, Peindl K, Patkar AA. American Psychiatric Association Annual Conference, New York, NY, May 2004.
64. *Relationship of Serotonin Transporter Polymorphism to Treatment Outcome in Cocaine Dependence* M. Mattila-Evenden M, Berrettini WH, Murray HW, Bilal L, Peindl K, Mannelli P, Patkar AA. American Psychiatric Association Annual Conference, New York, NY, May 2004.
65. *Mediators of Depression as a Predictor of Outcome in Cocaine Dependence* Mago R, Murray HW, Gottheil E, Vergare M, Mannelli, P, Thornton CC, Patkar AA. American Psychiatric Association Annual Conference, New York, NY, May 2004

66. *Tobacco Smoking Following Treatment for Cocaine Dependence* Murray HW, Leone FT, Vergare M, Mannelli, P, Peindl, K, Patkar AA. American Psychiatric Association Annual Conference, New York, NY, May 2004.
67. *Prolactin, Severity of Drug Use, and Treatment Outcome in Cocaine Dependence*. Frey AC, Berrettini WH, Murray HW, M, Mattila-Evenden M, Vergare M, Mannelli P. Patkar AA. American Psychiatric Association Annual Conference, New York, NY, May 2004.
68. *Low dose Naltrexone in opioid withdrawal*. Mannelli PM, Thornton C, Patkar AA , Gottheil E. American Psychiatric Association Annual Conference, Atlanta, May 2005.
69. *Pharmacotherapy of Alzheimers Disease. What Clinicians Know and need to know* Tharwani H, Masand PM, Patkar AA , Doraiswamy M. American Psychiatric Association Annual Conference, Atlanta, May 2005.
70. *A survey of beliefs and practices regarding use of second generation antipsychotics* Masand PM, Peindl K, Mago R, Tharwani H, Patkar AA American Psychiatric Association Annual Conference, Atlanta, May 2005.
71. *Psychiatric history as predictor of drug response in Irritable Bowel Syndrome*. Patkar AA, Masand PM, Krulewicz S, Varia I, Mannelli, PM J, Peindl K American Psychiatric Association Annual Conference, Atlanta, May 2005.
72. *Personality Profiles as predictors of response for fibromyalgia* Murray HW, Patkar AA, Masand PM, Krulewicz S, Jiang J, Peindl K American Psychiatric Association Annual Conference, Atlanta, May 2005.
73. *History of anxiety and depressive disorders and predictors of response in fibromyalgia* Patkar AA, Masand PM, Krulewicz S, Jiang J, Murray H Peindl K American Psychiatric Association Annual Conference, Atlanta, May 2005.
74. *Differences in peripheral mu opioid receptors among substance abusers*. Lindsay A, Zeiger A, Matthews P, Mannelli P, Peindl K, Handelsman L, Patkar AA. American Psychiatric Association Annual Conference, Atlanta, GA, May 2005.
75. *Low-Dose Naltrexone Administration Following Opiate Discontinuation*. Mannelli P, Thornton C, Weinstein S, Salazar C, Gottheil E. American Psychiatric Association Annual Conference, Atlanta, GA, May 2005.
76. *A Randomized, Controlled Trial of Paroxetine CR in Irritable Bowel Syndrome*. Masand P, Peindl K, Krulewicz S, Mannelli P, Varia I, Patkar A. American Psychiatric Association Annual Conference, Atlanta, GA, May 2005.
77. *Psychiatric History as a Predictor of Drug Response in Irritable Bowel Syndrome*. Peindl K, Patkar A, Krulewicz S, Mannelli P, Varia I, Masand P. American Psychiatric Association Annual Conference, Atlanta, GA, May 2005.
78. *History of Depressive and Anxiety Disorders as Predictors of Response in Fibromyalgia*. Patkar A, Peindl K, Krulewicz S, Mannelli P, Lindsay A, Masand P. American Psychiatric Association Annual Conference, Atlanta, GA, May 2005.
79. *Personality Profiles as Predictors of Response for Fibromyalgia*. Murray H, Patkar A, Peindl K, Krulewicz S, Dube E, Masand P. American Psychiatric Association Annual Conference, Atlanta, GA, May 2005.
80. *A Survey of Beliefs and Practices Regarding the Use of Second-Generation Antipsychotics*. Mago R, Patkar AA, Fazal F, Mannelli P, Masand P. American Psychiatric Association Annual Conference, Atlanta, GA, May 2005.
81. *Psychiatric history as predictor of drug response in Irritable Bowel Syndrome*. Masand PM, Krulewicz S, Leukauwa R, Peindl K, Patkar AA. NCDEU Annual Meeting, Boca Raton, Florida, June 2005.
82. *Personality Profiles as predictors of response for fibromyalgia* Patkar AA, Masand PM, Krulewicz S, Leukauwa R, Peindl NCDEU Annual Meeting, Boca Raton, Florida, June 2005.
83. *Substance related Psychotic disorders: Epidemiology and Pathophysiology*. Patkar AA. United States State Department and Duke University Continuing Medical Education Activity. Malta, Europe, August 31 2005.
84. *Substance related Psychotic disorders: Diagnosis and Treatment*. Patkar AA. United States State Department and Duke University Continuing Medical Education Activity. Malta, Europe, September 1 2005.
85. *Adolescent Substance Abuse: Problems and Pitfalls*. Patkar AA. Department of Psychiatry , University of South Carolina at Columbia, Continuing Medication Education Activity, Columbia, South Carolina, September 16 2005.
86. *Substance related Psychotic disorders: Epidemiology and Pathophysiology*. Patkar AA. United States State Department and Duke University Continuing Medical Education Activity. Washington D.C. September 12 2005.
87. *Substance related Psychotic disorders: Diagnosis and Treatment*. Patkar AA. United States State Department and Duke University Continuing Medical Education Activity. Washington D.C. September 13 2005.
88. *Substance related Psychotic disorders: Epidemiology and Pathophysiology*. Patkar AA. United States State Department and Duke University Continuing Medical Education Activity. Honolulu, Hawaii. October 3 2005.
89. *Substance related Psychotic disorders: Diagnosis and Treatment*. Patkar AA. United States State Department and Duke University Continuing Medical Education Activity. Honolulu, Hawaii October 4 2005.
90. *Comorbidity of alcohol use disorders with psychiatric illness*. Patkar AA Continuing Medical Education Activity organized by PSYCHCME. Bethesda, Maryland, October 7 2005.
91. *Comorbidity of alcohol use disorders with psychiatric illness*. Patkar AA Continuing Medical Education Activity organized by PSYCHCME. Philadelphia, PA, October 8 2005.
92. *Recognition and Management of Alcohol Dependence*. Patkar AA Continuing Medical Education Activity organized by PSYCHCME. Long Island, NY, October 14 2005.
93. *Recognition and Management of Alcohol Dependence*. Patkar AA Continuing Medical Education Activity organized by PSYCHCME. Boston, Mass, October 15 2005.
94. *Evidence-based approaches to treatment of alcohol dependence*, Patkar AA Oct 29, 2005, Annual PSYCHCME. Detroit, Michigan, CME symposium.

95. *Comorbidity of alcohol use disorders with psychiatric illness.* Patkar AA Continuing Medical Education Activity organized by PSYCHCME. Dearborn, Michigan, October 29 2005.
96. *Biological Basis of Substance Related Disorders in Schizophrenia.* Patkar AA Symposium at Indian Psychiatric Society annual meeting, Bombay, India, January 2006.
97. *Collaborative research across Countries: Example of Duke University Medical Center.* Patkar AA Symposium at Indian Psychiatric Society annual meeting, Bombay, India, January 2006.
98. *Clinical Trials: What is new on the horizon.* Patkar AA. Symposium at Indian Psychiatric Society annual meeting, Bombay, India, January 2006.
99. *Relationship of disinhibition and aggression to blunted prolactin response to meta-Chlorophenylpiperazine in cocaine dependent patients.* Hill KP, Peindl K, Mannelli P, Pae C, Patkar AA American Psychiatric Association Annual Conference, Toronto, Canada, May 2006.
100. *Intramuscular Pharmacotherapy of Agitation in Schizophrenia and Bipolar Disorders in Psychiatric Settings at Duke University Medical Center (D.U.M.C).* Tharwani H, Gersing K, Burchett B, Patkar A, Pae C, Masand P. American Psychiatric Association Annual Conference, Toronto, Canada, May 2006.
101. *Effectiveness of Escitalopram vs Venlafaxine XR in Major Depression in a Real World Clinical Setting.* Gersing K, Masand P, Burchett B, Pae C, Patkar A, American Psychiatric Association Annual Conference, Toronto, CA, May 2006.
102. *Aripiprazole augmentation for patients with major depressive disorder who failed to respond to antidepressant therapy.* Pae C, Patkar A, Andersson C, Lee C, Paik I, Masand P, American Psychiatric Association Annual Conference, Toronto, Canada, May 2006.
103. *A Comparison of Tolerability Profiles of Patients with Major Depressive Disorder receiving Selective Serotonin Reuptake Inhibitors (SSRIs) in a Naturalistic Clinical Care Setting.* Burchett B, Masand P, Patkar AA, Pae C, Gersing K. American Psychiatric Association Annual Conference, Toronto, CA, May 2006.
104. *A randomized, double-blind, placebo-controlled trial of methylphenidate extended release (OROS MPH) in the treatment of antidepressant-related sexual dysfunction.* Peindl K, Patkar A, Masand P, Mannelli P, American Psychiatric Association Annual Conference Toronto, Canada, May 2006.
105. *A Randomized, Double-Blind, Placebo-Controlled Trial of Sodium Oxybate in Fibromyalgia Syndrome [FMS].* Patkar A, Bennett R, Michalek J, Cook R, Perera P, Masand P. American Psychiatric Association Annual Conference, Toronto, CA, May 2006.
106. *Relationship of major depression to severity of drug use, Learned Helplessness, treatment readiness, and coping in cocaine dependence.* Clodfelter T, Patkar AA, Manelli P, Peindl K, Lynch T, Rosenthal Z. American Psychiatric Association Annual Conference Toronto, Canada, May 2006.
107. *Serotonin transporter gene and moderators of prolactin response to meta-Chlorophenylpiperazine in African American cocaine abusers and controls.* Mannelli P, Peindl K, Patkar A, Tharwani H, Ajwani N, Mathew T. American Psychiatric Association Annual Conference, Toronto, Canada, May 2006.
108. *Issues Related to Treatment Compliance in Bipolar Patients.* Narasimham M, Masand P, Patkar A, Peindl K. American Psychiatric Association Annual Conference, Toronto, Canada, May 2006.
109. *Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Augmentation with OROS Methylphenidate in Treatment-Resistant Depression.* Masand PS, Peindl K, Hooper-Wood C, Ciccone P, Pae C, Mannelli P, Patkar A. NCDEU Annual Meeting being held June 12-15th, 2006 at Boca Raton
110. *A Randomized, Double-Blind, Placebo-Controlled Trial of Sodium Oxybate in Fibromyalgia Syndrome (FMS)* Patkar AA, Bennett R, Michalek J, Cook H, Perera P, Masand PS. NCDEU Annual Meeting being held June 12-15th, 2006 at Boca Raton
111. *A Comparison of Tolerability Profiles of Patients with Major Depressive Disorder Receiving Selective Serotonin Reuptake Inhibitors (SSRIs) in a Naturalistic Clinical-Care Setting.* Burchett B, Masand PS, Patkar AA, Pae C, Gersing K. NCDEU Annual Meeting being held June 12-15th, 2006 at Boca Raton.
112. *A Randomized, Double-Blind, Placebo-Controlled Trial of Methylphenidate Extended Release (OROS MPH) in the Treatment of Antidepressant-Related Sexual Dysfunction.* Pae C, Peindl K, Masand P, Hooper-Wood C, Ciccone P, Mannelli P, Patkar A. NCDEU Annual Meeting being held June 12-15th, 2006 at Boca Raton
113. *Treatment of Alcohol Dependence.* CME symposium on Updates in Psychiatry. Patkar AA North Carolina Psychiatric Association Annual Meeting, Asheville, NC, Sept 14-16, 2006
114. *Role of Oxybate in Fibromyalgia.* Invited presentation. Patkar AA US Psychiatric Congress, Annual Meeting, New Orleans, LS, Nov 17-20, 2006
115. *Pharmacotherapy of Substance Abuse.* Patkar AA. Governors Institute on Alcohol and Drug Abuse, State of NC Practice Improvement Collaborative meeting Dec 11, 2006, Raleigh, NC
116. *Alcohol and prescription drug misuse in the elderly.* Patkar AA. Symposium at Indian Psychiatric Society annual meeting, Chennai, India, January 2007.
117. *Advances in psychopharmacological treatment of substance abuse.* Patkar AA. Symposium at Indian Psychiatric Society annual meeting, Chennai, India, January 2007.
118. *Treatment of Alcohol Dependence.* CME symposium on Updates in Psychiatry. Patkar AA Governors Institute on Alcohol and Drug Abuse, State of NC Practice Improvement Collaborative meeting Feb 23, 2007, Pinehurst, NC

119. *Screening and Brief Interventions in Substance Abuse.* Patkar AA Governors Institute on Alcohol and Drug Abuse, State of NC Practice Improvement Collaborative meeting Feb 23, 2007, Pinehurst, NC
120. *Sexual Addiction: Another form of addictive disorder?* Invited presentation Indian-American Psychiatric Association Symposium. American Psychiatric Association Annual Conference San Diego, CA, May 2007.
121. *Bupropion reinstates cocaine seeking in rats.* Ahn CS, Gopalan R, Mannelli P, Patkar AA, Lee T, Davidson C, Ellingwood E. American Psychiatric Association Annual Conference San Diego, CA, May 2007.
122. *Bupropion reinstates cocaine seeking in rats.* Ahn CS, Gopalan R, Mannelli P, Patkar AA, Lee T, Davidson C, Ellingwood E. American Psychiatric Association Annual Conference San Diego, CA, May 2007.
123. *Association between platelet serotonin transporter availability, m-CPP response and treatment outcome in cocaine dependence.* Patkar AA, Mannelli P, Peindl K, Lee T, Kuhn C, Ellingwood E. American Psychiatric Association Annual Conference San Diego, CA, May 2007, May 2007.
124. *An open label, rater-blinded, trial of escitalopram in major depression with atypical features.* Patkar AA, Ajwani N, Pae C-U, Han C, Mannelli P, Peindl K, Masand PS . American Psychiatric Association Annual Conference San Diego, CA, May 2007.
125. *Sexual Addiction: A new form of Addictive Disorder?* Patkar AA Indian American Psychiatric Association Annual Scientific Symposium, APA annual Meeting May18-24, 2007, San Diego, CA. Keynote speaker and recipient, Outstanding Academician Award.
126. *Sexual abuse and response to paroxetine CR in Irritable Bowel Syndrome.* Pae CU, Masand PS, Krulewicz S, Han C, Mannelli P, Peindl K, Patkar AA. New Clinical Drug Evaluation Unite (NCDEU) meeting, Boca Raton, FL, June 2007.
127. *Sexual abuse, health status and response to paroxetine CR in fibromyalgia.* Patkar AA, Pae CU, Krulewicz S, Han C, Mannelli P, Peindl K, Masand PS . New Clinical Drug Evaluation Unite (NCDEU) meeting, Boca Raton, FL, June 2007.
128. *Management of Drug Intoxication and Withdrawal.* Patkar AA Guilford LME Best Practices workshop July 30, 2008
129. *Ropinirole XL Augmentation of Antidepressant Resistant Depression.* DeBattista C, Patkar AA, Hawkins J, Han C, Rowena G. American Psychiatric Association Annual Conference, Washington, DC, May 2008
130. *Effective Drugs in Psychiatry: Magic Bullets or Hand Grenades?* Marks DM, Patkar AA. 2nd World Conference on Magic Bullets, Nuremberg, Germany, October 5, 2008.
131. *Translational Research in the Elderly.* Patkar AA Annual National Conference of Indian Psychiatric Society, Agra, India, 8th-11th January, 2009
132. *Screening and Brief Interventions for underage drinkers in underserved populations.* Patkar AA, Kemper A, Dolor R, Anderson J, Thanaseelan J, Robinson L, Peindl K, Hubbard R. American Psychiatric Association Annual Conference, San Francisco, May 2009
133. *Effects of adjunctive armodafinil in schizophrenia.* Patkar AA, Kane JM, Keefe SE, Youakim JM, Tiller J, D'Souza DC American Psychiatric Association Annual Conference, San Francisco, May 2009
134. *Transcending the Boundaries Workshop: "Advancing the Neuroscience of Addiction: From Molecules to Behavior" Addiction Research: Blending science with clinical practice.* Duke Institute of Brain Sciences Workshop, November 12, 2009
135. *The Difficult to treat Substance Abuse Patient* Patkar AA Annual National Conference of Indian Psychiatric Society, Agra, India, 17th-21th January, 2010

Grand Rounds, Lectures and CMEs (selected from over 100)

1. Addiction and the brain, Best Practices Lectures Organized through National Institute on Drug Abuse (NIDA) North Carolina Node for Community Treatment Programs, July 26, 2005 Raleigh, NC
2. Adolescent Drug Abuse, Best Practices Lectures Organized through National Institute on Drug Abuse (NIDA) North Carolina Node for Community Treatment Programs, August 15, 2005, Durham, NC
3. Substance related psychotic disorders I: Epidemiology and Comorbidity. Patkar AA US State Department (Foreign Office) CME Lectures Malta, Europe August 29 – September 1, 2005
4. Substance related psychotic disorders II: Evaluation and Treatment Patkar AA US State Department (Foreign Office) CME Lectures Malta, Europe August 29 – September 1, 2005
5. North Carolina Psychiatric Association Annual Meeting, Wilmington, NC, Sept 7-9, 2006 Patkar AA: Co-occurring Disorders CME symposium on Updates in Psychiatry
6. Dept of Psychiatry, University of SC at Columbia Grand Rounds, Columbia, SC Sept 15 2005 Patkar AA: Adolescent Drug Abuse; Problems and Pitfalls.
7. Prescription Opioid Abuse, Best Practices Lectures Organized through National Institute on Drug Abuse (NIDA) North Carolina Node for Community Treatment Programs, October 18, 2005, Durham, NC
8. Co-occurring Disorders, Best Practices Lectures Organized through National Institute on Drug Abuse (NIDA) North Carolina Node for Community Treatment Programs, November 8, 2005, Wilmington, NC
9. Evidence-based Treatments of Substance Abuse, Best Practices Lectures Organized through National Institute on Drug Abuse (NIDA) North Carolina Node for Community Treatment Programs, March 15, 2006, Greensboro, NC
10. Grand Rounds, WakeMed Hospital, Raleigh, NC May 2006. Patkar AA: Biological Markers in Addiction
11. What's new in the field of drug Addiction, Best Practices Lectures Organized through National Institute on Drug Abuse (NIDA) North Carolina Node for Community Treatment Programs, July 20, 2006, Knoxville, TN

12. The NIDA Clinical Trials Network. Patkar AA Georgia Psychiatric Association Annual Meeting, Jacksonville, FL, August 12-15, 2006
13. Addiction in rural areas: a growing problem. Patkar AA. Georgia Psychiatric Association Annual Meeting, Jacksonville, FL, August 12-15, 2006
14. Integrated treatments in Substance Abuse, Best Practices Lectures Organized through National Institute on Drug Abuse (NIDA) North Carolina Node for Community Treatment Programs, August 17, 2006, Statesboro, Georgia
15. Grand Rounds, Cherry Hospital, Annual CME Program, Wilmington, NC, August 18, 2007 Patkar AA: Treatment of Substance Abuse
16. "Answering Questions That Change Practice: The Role of Practical Clinical Trials (PCTs)" Patkar AA Co-Organizer and Speaker at NIDA CTN Workshop October 1-2, 2007 Bethesda, MD.
17. Grand Rounds, Rosalind Franklin University, Chicago, Nov 1, 2007 Patkar AA: Novel Pharmacotherapies in Substance Abuse
18. Grand Rounds, University of Pennsylvania, Philadelphia, December 3, 2007 Patkar AA: Sexual Addiction: Diagnostic Dilemmas.
19. Grand Rounds, Walter Reed Hospital, Washington DC, Jan 17, 2008. Patkar AA: Dual Diagnosis: Challenges and Advances
20. Duke AHEC CME program, Sandhills LME, Pinehurst, NC, March 17, 2008 Patkar AA: Best Practices in Treatment of Substance Abuse
21. Grand Rounds, Dorothea Dix Hospital, Raleigh, NC March 19, 2008. Patkar AA Nicotine Addiction: Neurobiology and Treatment.
22. North Carolina AHEC CME symposium, Guilford Mental Health Center, Greensboro, NC, April 24, 2008 Patkar AA: Treatment of Co-occurring Disorders
23. Grand Rounds, John Umstead Hospital, July 24, 2008 Patkar AA: Treatment of Adolescent Drug Addiction
24. Grand Rounds, Duke University Dept of Psychiatry, Patkar AA, July 24, 2008.
25. Grand rounds Howard University, Washington DC, August 15, 2008. Patkar AA. Genetics of Addictive Disorders.
26. Grand Rounds, Eastern State Hospital, Williamsburg, VA, Sept 13, 2008. Patkar AA Mood Disorders and Substance Abuse: Where is the overlap?
27. Grand Rounds, Dept of Psychiatry, University of NC at Charlotte, NC, Sept 23, 2008 Patkar AA: Translational Research: From Molecules to Man
28. Invited lecture: Korean College of Neuropsychopharmacology Annual Meeting March 26-27, 2009. Patkar AA Optimal psychopharmacology: Pathway to wellbeing
29. Grand Rounds. Eastern Carolina University, Greenville, NC, April 21, 2009 Patkar AA Prescription opioid dependence: Update of therapeutic strategies
30. Guilford County Mental Health Services Training Workshop. June 17, 2009. Patkar AA Opioid Treatment: What clinicians need to know.
31. Medical Update Series, NC Medical Society, June 22, 2009 Patkar AA Medical management of substance abuse
32. Patkar AA: *Improving smoking cessation strategies*. The 3rd North Carolina COPD Task Force Symposium University of North Carolina Chapel Hill, June 24 2009
33. DCRI Research Conference: October 6, 2009: Evidence based treatment strategies for substance abuse.
34. Grand Rounds, Riverside Medical Center, Suffolk Smoking Cessation. It can be done! Patkar AA, February 6, 2010

NIH COMMITTEES:

NIMH Interventions Review Committee (ITV)

NIH (NIDA) Reviewer for CEBRA (Cutting Edge Basic Science Research)

CONSULTANT/ADVISORY BOARD: Bristol Myers Squibb Inc.

Pfizer Inc

GlaxoSmithKline

Reckitt Benckiser Inc.

Forest Research Institute

Titan Pharmaceuticals

SPEAKERS BUREAU

Pfizer, Bristol Myers Squibb, GlaxoSmithKline, Reckitt Benckiser, Merck, Cephalon

PROFESSIONAL AWARDS & SPECIAL RECOGNITION:

-
- Best Doctors in North Carolina 2009
- Patient Choice Award 2009
- Academician of the year award-2007. Indian American Psychiatric Association
- Selected for the Seventh Annual Research Colloquium for Junior Investigators, APA annual meeting, May 2002.
- Best paper award Annual Conference of the American Society of Addiction Medicine, Atlanta, Georgia April 2002. Paper: Predicting treatment-outcome in cocaine dependence from admission urine drug screen and peripheral serotonergic measures.
- Selected for “Future Leaders in Psychiatry” meeting, Scottsdale Arizona, 2000.
- American Academy of Addiction Psychiatry Jaanssen Research Award for Young Investigators, 1999.
- Second Annual Pfizer Psychiatry Resident of the Year Award, 1997.
- Lilly Fellowship Award, Society of Biological Psychiatry, 1997
- Daniel Lieberman Award for best paper by a Jefferson Psychiatry Resident, 1997.
- University Merit Scholarship for honors and first rank at Diploma in Psychological Medicine
- Honors at M.D. - Psychiatry
- University Merit Scholarship for graduating with honors from Medical School.

ORGANIZATION & PARTICIPATION:

Committee appointments as follows:

National

- Research Committee, American Academy of Addiction Psychiatry, 2000-present
- Nicotine dependence Committee, American Association of Addiction Medicine, 2001-present
- Organizing secretary, Indian-American Psychiatric Association, Philadelphia Chapter 2001- 2004
- Medical Advisory Committee-Caron Foundation 2003-present
- Indian –American Psychiatric Association, Life Member

Local

- Member Duke University Center for AIDS Research
- North Carolina Psychiatric Association Addictions Committee 2005- present
- North Carolina State Treatment Improvement for Substance Abuse Committee 2005 - present
- Durham County Steering Committee for Addiction Treatment Services, 2005-present
- Treasurer: Triangle Indian American Physicians Society, 2006-present
- Institutional Review Board, Thomas Jefferson University, 2003-2004
- Research Committee , Thomas Jefferson University, 2003-2004
- Advisory Committee for Clinical Research Development, Thomas Jefferson University, 2003-2004

- Committee on Addictions, Philadelphia County Medical Society, 1999-2004
- Member, Physicians Health Committee, Thomas Jefferson University Hospital, 2000-2004.
- Planning committee: Philadelphia Psychiatric Society Annual Scholars symposium 2004.

Editorial Board

Journal of Addictive Diseases
Journal of Dual Diagnosis Treatment
Open Pharmacology

Journal Reviewer

- *Psychiatric Services* 1998-continuing.
- *American Journal on Addictions* 2000-continuing
- *Progress in Neuropsychopharmacology & Biological Psychiatry* 2003-continuing
- *Journal of Nervous and Mental Disease* 2002-continuing
- *Addiction* 2001-continuing
- *American Journal of Psychiatry* 2001-continuing
- *Addiction Biology* 2003-continuing
- *Aging and Mental Health* 2006-continuing
- *Psychiatry Research* 2002-continuing
- *Biological Psychiatry* 2003-continuing
- *Schizophrenia Research* 2003-continuing
- *Current Drugs* 1999-continuing
- *Medical Science Monitor* 2003-continuing
- *International Journal of Clinical Practice* 2003-continuing
- *Neuroscience Letters* 2005-continuing
- *Pharmacogenetics* 2004-continuing
- *Experimental and Clinical Psychopharmacology* 2004-continuing
- *BMC Public Health* 2004-continuing
- *Future Neurology* 2006-continuing
- *Drug and Alcohol dependence* 2006-continuing

Examiner American Board of Psychiatry and Neurology.

Previous appointments

- Chief Editor, Jefferson Journal of Psychiatry, 1996-97.
- Member: Medical Staff Audit Committee, Mapperley Hospital, Nottingham, 1994.
- Member: Research Committee University Hospital, Nottingham, 1993-94.
- Library Representative: Junior Medical Staff Committee, Nottingham, UK (1992-1994).

TEACHING:

Medical students at Jefferson Medical College

Second year: Pharmacology 401 Course.

Third year: Didactics on Addictive disorders.

Clinical supervision.

Fourth Year: Research Electives.

Psychiatry Residents at Thomas Jefferson University Hospital:

First Year: Lectures on Schizophrenia

Second Year: Lectures on Addictive Disorders

Third Year: Clinical supervision

Fourth Year: Clinical supervision and electives.

Post Doctorates and Junior Faculty

Didactics and Mentorship on the NIH funded K-30 program for Masters in Clinical Research. Thesis Advisor to Raman Gopalakrishnan, MD (graduated) and Louai Bilal, MD (ongoing).

Graduate Students at Thomas Jefferson University

Thesis Committee member for

- Jermaine Jones-Masters in Pharmacology. Thesis: Differences in opioid receptors and immune response among HIV positive heroin abusers and HIV negative heroin abusers.
- Anthony Nizio-Masters in Pharmacology. Thesis: A novel technique for direct immunoassay for small quantities of morphine in body fluids.

EXTERNAL SUPPORT

FEDERAL & STATE RESEARCH GRANTS

a) Active:

1. *"National Drug Abuse Treatment Clinical Trials Network (CTN)"*

<u>Grant and Sponsor</u>	<u>Duration</u>
U10 (DA14711 (PI: Brady) NIH (NIDA)	September 2010 – September 2015

The long-term objective is to establish a national network of regional research centers and collaborating community treatment programs to design and conduct multi-center clinical trials of behavioral and medical interventions to establish effective treatments and to understand the process of technology transfer.

2. Novel Ondansetron Formulation for Combination Treatment of Psychostimulant Abuse

<u>Grant and Sponsor</u>	<u>Duration</u>
1RC2DA028905-01 (PI Lee, Mangum, Patkar) NIDA/NIH	9/30/09-9/29/11

This GO grant uses a translational approach to test combination of a delayed release ondansetron and immediate release methylphenidate in stimulant dependence

3. *Targeted Capacity Expansion Program for Substance Abuse Treatment and HIV/AIDS"*

<u>Grant and Sponsor</u>	<u>Duration</u>
1 U79-TI014386-01 (PI Whetten) SAMHSA	9/30/08-9/29/13

The expansion grant's purpose is to ensure that HIV-positive people living in the Raleigh-Durham MSA have increased access to culturally sensitive substance abuse and HIV prevention and treatment services.

4. *Gene Environment Development Interaction for Substance Abuse*

<u>Grant and Sponsor</u>	<u>Duration</u>
1 U10-DA 16411-01 (PI Costello) NIDA/NIH	9/30/08-9/29/13

This project examines the contributions of genetic, developmental and environmental risk factors for substance abuse.

5 *Integrated Treatment of Persons with Co-Occurring HCV and Alcohol Use/Abuse*

<u>Grant and Sponsor</u>	<u>Duration</u>	<u>Effort</u>
R21AA017252-01A1(PI Muir) NIAAA/NIH	9/30/08-9/29/10	5%

This study examines the implementation and alcohol and health outcomes of an integrated HCV-alcohol treatment program.

b) Completed**2. Data and Statistical Center for Clinical Trials Network**

<u>Grant and Sponsor</u>	<u>Duration</u>
--------------------------	-----------------

HHSN271200522071C (PI: Blazer)

NIDA/NIH 5/1/05– 4/30/10

This is a contract from NIDA to manage data and statistical analyses for all clinical trial run through the Clinical Trials Network.

Improving Co-occurring Disorder Care in Rural Areas via Technology Enhancements

<u>Grant and Sponsor</u>	<u>Duration</u>
--------------------------	-----------------

5R01DA022074-03 (PI: Mathew)

NIDA/NIH 9/15/2006 – 7/31/2009

The goal of this study has been to evaluate the feasibility of implementing telemedicine-based assessments of co-occurring disorders and HIV-risk in underserved areas.

Integrative Treatment Model for Mentally Ill, Pregnant Women in Russia

<u>Grant and Sponsor</u>	<u>Duration</u>
--------------------------	-----------------

1 U99-TI014386-01 (PI Whetten) 9/1/05-8/31/10

NIMH/NIH

This international project proposes to implement an integrated model to address mental illness, substance abuse and HIV in teenage pregnant women in St. Petersburg, Russia.

Peripheral opioid receptors in cocaine abusers.

<u>Grant and Sponsor</u>	<u>Duration and costs</u>	<u>Effort</u>	<u>total costs</u>
--------------------------	---------------------------	---------------	--------------------

Subcontract (PI: Patkar) 07/2003- 06/2006 1% \$20,000

NIH (NIDA)

This is a part of an intramural NIDA research project (PI Gorelick) to examine central and peripheral opioid receptors in cocaine abusers.

Low dose Naltrexone in opiate withdrawal

<u>Grant and Sponsor</u>	<u>Duration</u>	<u>Effort</u>	<u>total costs</u>
--------------------------	-----------------	---------------	--------------------

1R21DA016304-01 (PI: Mannelli) 06/2003- 01/2008 5% \$588,750

NIH (NIDA)

This investigates w the role of low dose naltroxone given concomitantly with methadone during detoxification of opiate dependent patients.

. "National Drug Abuse Treatment Clinical Trials Network (CTN)" (Multi-center clinical trials of potentially effective behavioral and medical treatments in real world settings)

<u>Grant and Sponsor</u>	<u>Duration</u>	<u>Effort</u>	<u>Total costs</u>
--------------------------	-----------------	---------------	--------------------

U10 (DA13711-01 (PI: Hubbard)

NIH (NIDA) Jan 2001 – June 2007 15% \$10,224,000

The long-term objective is to establish a national network of regional research and training centers and collaborating community treatment programs to design and conduct multi-center clinical trials of behavioral and medical interventions to establish effective treatments and to understand the process of technology transfer.

Starting Treatment with Agonist Replacement Therapies (START): Data & Statistical Center

<u>Grant and Sponsor</u>	<u>Duration</u>	<u>Effort</u>
--------------------------	-----------------	---------------

HHSN271200522071C (Clinical PI: Patkar)

NIH (NIDA)

September 2005 – July 2010

15%

This is a contract from NIDA to manage data and statistical analyses for the START study, a collaborative study between NIDA and Reckitt-Benckiser as requested by the FDA for a liver toxicity study of buprenorphine-naloxone combination versus methadone.

PARTNER: Prevention approaches to rural underage drinking

Grant and Sponsor	Duration
-------------------	----------

1U01-AA-016473-01 (PI: Hubbard)

NIH (NIAAA) September 2006– July 2009

The long-term objective is to establish a national network of clinical sites to design and conduct multi-center clinical trials of behavioral and medical interventions to address rural underage drinking.

Buprenorphine/Naloxone facilitated rehabilitation for opioid dependent adolescents (NIDA- CTN- 0010 protocol)

Grant and Sponsor	Duration	Effort	Total costs
-------------------	----------	--------	-------------

NIDA- CTN- 0010 (PI: Patkar)

NIH (NIDA) Jan 2001 – June 2007 10% \$184, 000 per year

This CTN supported protocol aims to compare two different schedules of buprenorphine/naloxone treatments for opioid dependent adolescents.

Serotonin and cocaine dependence: Treatment implications.

Grant and Sponsor	Duration	Effort	total costs
-------------------	----------	--------	-------------

1R21DA0115504-01 (PI: Patkar) 07/2003- 06/2006 25% \$588,750

NIH (NIDA)

This study investigates whether a pharmacological matching strategy using serotonergic agents and platelet paroxetine binding will improve outcomes in cocaine patients.

Serotonergic function and treatment outcome in cocaine abusers.

Grant and Sponsor	Duration	Effort	Total costs
-------------------	----------	--------	-------------

KO800DA-97-340 (PI: Patkar) 07/1997- 06/2004 75% \$658,800

NIH (NIDA)

This project investigates whether there are neurobiological and genetic differences in serotonin function among cocaine abusers and whether these measures influence treatment outcome.

A genetic study of Nicotine Dependence

Grant and Sponsor	Duration	Effort	Total costs
-------------------	----------	--------	-------------

Price Foundation (Jefferson PI: Patkar) 03/1999- 02/2001 20% \$120,000

This grant investigates whether polymorphisms in several genes contribute toward susceptibility for nicotine dependence.

Tobacco control education in medical school curricula.

Grant and Sponsor	Duration	Effort	Total costs
-------------------	----------	--------	-------------

Commonwealth of Pennsylvania (PI: Leone) 07/2002- 06/2005 15% \$218,750

This project investigates whether a tobacco education curriculum influences awareness and behaviors of medical students with respect to smoking cessation interventions

INDUSTRY SPONSORED CLINICAL TRIALS

a) Active

- *A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Exploratory Efficacy and Safety Study of SPD489 in Adults 18-55 years with Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant. (Protocol Number: SPD489-203) Grant and Sponsor: Shire (PI: Patkar).*
- *A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults with Clinically Significant, Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder. (Protocol Number: SPD489-205) Grant and Sponsor: Shire (PI: Patkar).*
- *Treatment for Bipolar Disorder: Acute & Prophylactic Efficacy with Citalopram. (PI: Patkar)*
- *A Randomized, Double-Blind, Placebo & Active Controlled, Multi-center Study of Probuphine® in Patients with Opioid Dependence. (Protocol Number: PRO-806) Grant and Sponsor: Titan Pharmaceuticals Inc. (PI: Patkar).*
- *Predictors of response to Augmentation with Ziprasidone (Geodon®) in Major Depressive Disorder: A 13-week, Double-Blind, Placebo-Controlled, Cross-Over Trial. Grant and Sponsor: Independent Research Award (Investigator Initiated) through Pfizer Inc.*
- *A randomized, Double blinded, Placebo-controlled, parallel-group, phase 2 study of the safety and efficacy of ABT-126 in the treatment of cognitive deficits in Schizophrenia. (CDS). (Protocol Number: M10-854) Grant and Sponsor: Abbott (PI: Patkar).*

b) Completed

- *A Randomized, Double-blind, Parallel-group, Flexible-dose Study Exploring the Neurocognitive Effect of Sertindole versus Quetiapine in Patients with Schizophrenia using the MATRICS Consensus Cognitive Battery (MCCB™). (Protocol number: 11723A) Grant and Sponsor: Lundbeck (PI: Patkar)*
- *A Phase 2 6-Week, Double-Blind, Placebo-Controlled, Multicenter trial of Varenicline Tartrate (CP-526, 555) for Cognitive Impairment in Subjects with Schizophrenia (Protocol number: A3051100) Grant and Sponsor: Pfizer (PI: Patkar)*
- *A Randomized, Double-Blind, Placebo-Controlled Trial of Ziprasidone (Geodon®) for the Depressive Mixed State (Investigator initiated) Grant and Sponsor: Pfizer (PI: Patkar)*
- *An Open-Label, Rater-Blinded, Flexible-Dose, 8-Week Trial of Escitalopram (Lexapro®) in Patients with Generalized Anxiety Disorder and HIV (Investigator initiated). Sponsor Forest Research Institute (PI: Patkar)*
- *A Phase 3B 12-Week, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Varenicline Tartrate (CP-526,555) 1 mg BID for Smoking Cessation in Subjects with Schizophrenia and Schizoaffective Disorder (Protocol number: A3051072) Grant and Sponsor: Pfizer (PI: Patkar)*
- *An open-label, Multi-center Retreatment Study of Probuphine in Patients with Opioid Dependence (Protocol ID # PRO-807) Grant and Sponsor: Titan Pharmaceuticals, Inc. (PI: Patkar)*
- *A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study of Probuphine in Patients With Opioid Dependence (protocol # PRO-805) Grant and Sponsor: Titan Pharmaceuticals, Inc. (PI: Patkar)*

- *A Study to Evaluate the Performance Characteristics and Potential Clinical Utility of Neuropsychological Tests for Use in Studies of Patients with Schizophrenia.* Sponsor Merck (PI: Patkar)
- *A Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Xyrem (sodium oxybate) in Subjects with Fibromyalgia (protocol #06-008)* Sponsor Jazz Pharmaceuticals, Inc. (PI: Patkar)
- *A Six-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible Doses of Oral Ziprasidone in Outpatients with bipolar depression (protocol # A1281139)* Sponsor Pfizer, Inc. (PI: Patkar)
- *Ropinirole CR as an Adjunctive Agent in the Treatment of Major Depression (Investigator initiated).* Sponsor: GSK (PI Patkar)
- *A 4-week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy to Olanzapine in Adults With Cognitive Deficits Associated With Schizophrenia (protocol # 2003)* Sponsor Cephalon (PI: Patkar)
- *A Multicenter, Double-Blind, Study on the Efficacy and Safety of Aripiprazole in Combination with Lamotrigine in the Long-term Maintenance Treatment of Patients with Bipolar I Disorder With a Recent Manic or Mixed Episode (protocol # CN138-392-070)* Sponsor Bristol-Myers Squibb (PI: Patkar)
- *An Open-Label, Rater-Blinded, Flexible-Dose, 8-Week Trial of Escitalopram (Lexapro®) in Patients with Major Depression with Atypical Features (Investigator initiated).* Sponsor Forest Research Institute (PI: Patkar)
- *A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Continuing Lithium or Valproic Acid/Divalproex Sodium for the Treatment of an Acute Manic or Mixed Episode (protocol # A7501008)* Sponsor Pfizer/Organon (PI: Patkar)
- *A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients with Bipolar I Disorder with a Major Depressive Episode (protocol # CN138-096-062)* Sponsor Bristol-Myers Squibb (PI: Patkar)
- *A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (50 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects with Schizophrenia (protocol # R092670-PSY-3003)* Sponsor Johnson & Johnson (PI: Patkar)
- *Paroxetine-CR (Paxil-CR) in the treatment of patients with Fibromyalgia Syndrome: A randomized, double blind, parallel group, flexible dose, placebo controlled trial (Investigator initiated)* Sponsor GlaxoSmithKline (PI: Patkar)
- *Two-Site, Double-Blind, Flexible-Dose, Placebo-Controlled Study of the Efficacy, Tolerability, & Safety of Paroxetine – Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) followed by an open label extension (Investigator initiated).* Sponsor GlaxoSmithKline (PI: Patkar)
- *A Parallel Group, Randomized, Double-blind, placebo-Controlled Trial of Augmentation with Methylphenidate extended release (Concerta®) In Patients With Treatment-Resistant Depression. (Investigator initiated).* Ortho McNeil (PI: Patkar)
- *A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem® (sodium oxybate) with Placebo for the Treatment of Fibromyalgia.* Jazz Pharmaceuticals (PI: Patkar)

- *A Double-Blind Flexible Dose Comparison of Escitalopram, Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder*(protocol#SCT-MD-31). Sponsor Forest Pharmaceuticals (PI: Patkar)
- *An Open-Label Study Of Aripiprazole (Abilify®) in the Treatment of Delirium.* (Investigator initiated). Sponsor: Bristol Myers Squibb (PI: Patkar)
- *An Open-Label Study Of Aripiprazole (Abilify®) As An Augmentation Agent In Patients With Treatment-Resistant Depression.* (Investigator initiated). Sponsor Bristol Myers Squibb (PI: Patkar)
- *A multicenter, open-label, flexible-dose, parallel-group evaluation of the cataractogenic potential of quetiapine fumarate (SEROQUEL™) and risperidone (RISPERDAL™) in the long-term treatment of subjects with schizophrenia or schizoaffective disorder* (protocol# 5077IL-0089). Sponsor: Astra Zeneca (PI: Patkar)
- *A multicenter, randomized, double-blind, placebo controlled study of the safety and efficacy of aripiprazole of aripiprazole as adjunctive therapy in the treatment of patients with major depression* (protocol # CN138-139). Sponsor Bristol Myers Squibb (PI: Patkar)
- *“A Multicenter, Double-Blind, Placebo Controlled, Two-Arm, Flexible-Dose Efficacy and Safety Trial With Org 24448 (250 to 750 mg b.i.d.) in Subjects With Acutely Exacerbated Schizophrenia”* Sponsor: Organon USA. (PI: Patkar)
- *A 6½ Month, Multicenter, Randomized, Double-blind, Placebo-Controlled Comparison of 300mg/day of Extended-Release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Affective Disorder in Subjects with a History of Seasonal Affective Disorder* Principal Investigator (protocol # AK130936, sponsor GlaxoSmithKline) (2002-03).
- *A twelve-week double blind, placebo-controlled, randomized, multicenter study evaluating the safety and efficacy of a flexible-dose strategy for CP-526,555 in smoking cessation.* Co-Investigator (Principal Investigator Frank T Leone, MD). Sponsor Pfizer Inc. (2002-03).
- *An international, multicenter, large simple trial (LST) to compare the cardiovascular safety of ziprasidone and olanzapine* Principal Investigator. (protocol # A1281062, Sponsor Pfizer Inc. (02-03).
- *A forty-week, double blind multicenter, nontreatment extension to study A3051016 evaluating the efficacy of a flexible-dosing strategy (0.5 to 2.0 mg total daily dose) in smoking cessation.* Co-Investigator(Principal Investigator Frank T Leone, MD). Sponsor Pfizer Inc. (2001-02).
- *A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of ropinirole in patients suffering from Restless Legs Syndrome.* Co-Investigator (Principal Investigator Karl Doghramji, MD). Sponsor Glaxo Smith Kline Inc (2002-03).
- *A 12-week randomized, placebo controlled, double-blind study of Modafanil (Provigil) in the treatment of excessive daytime sleepiness in depression.* Co-Investigator (Principal Investigator Karl Doghramji, MD). Protocol # C1538a/413, Sponsor Cephalon Inc (2002-03).
- *A randomized open-label rater-blinded assessment of optimal treatment change strategy to risperidone for patients intolerant of olanzapine (risperidone rescue study).* Principal Investigator. (Protocol #RIS-USA-250. Sponsor Janssen Pharmaceuticals (2001-02).
- *A flexible dose comparison of the safety and efficacy of LU26-054 (escitalopram) and placebo in the treatment of major depressive disorder* Co-Investigator ((Principal Investigator Ronald Serota, MD). Sponsor Forest Pharmaceuticals Inc. protocol no SCT-MD-02(2000-2001).

- *A flexible dose comparison of the safety and efficacy of escitalopram and placebo in the treatment of generalized anxiety disorder* Co-Investigator (Principal Investigator Ronald Serota, MD). Sponsor Forest Pharmaceuticals Inc. protocol no SCT-MD-07(1999-2000).

REFERENCES: Available on request.